Pattaya, Thailand

November 28-30, 2014

4th Asian and Oceanian Parkinson's Disease and Movement Disorders Congress

Final Program

International Parkinson and Movement Disorder Society
Asian & Oceanian Section

Main Organizer

THAI PDMDS

Host Organizer

International Parkinson and
Movement Disorder Society
Asian & Oceanian Section

Save the Date

September 2016
MANILA, PHILIPPINES

5th Asian and Oceanian Parkinson's Disease and Movement Disorders Congress

Table of Contents

Welcome

Louis Tan

Roongroj Bhidayasiri

Dear Colleagues,

On behalf of the International Parkinson and Movement Disorder Society (MDS) and the Thai Parkinson's Disease – Movement Disorder Society we would like to formally welcome you to Pattaya, Thailand for the 4th Asian and Oceanian Parkinson's Disease and Movement Disorders Congress (AOPMC).

The AOPMC Scientific Program Committee has worked very hard to bring you a diverse program that covers a wide range of topics on Parkinson's disease and other movement disorders from both a basic science and clinical perspective. You will have the opportunity to hear from world renowned experts in the field of Movement Disorders. This conference is designed to highlight the most recent advances and fundamental research and treatment strategies related to movement disorders. We hope you will take part in the many exciting educational opportunities the AOPMC has to offer.

One of the first beach resorts in Thailand, Pattaya draws in millions of tourists each year for activities ranging from water sports to indulging in some of Thailand's freshest seafood. Only 147 km from Bangkok, it is the closest of Thailand's major beach resorts to the capital city. The temperatures in this vibrant coastal city range from highs of 30°C (86°F) to lows of 20°C (73°F), enticing tourists in even the coldest months. In addition to exotic cuisine and splendid scenery, Thailand is widely known for the warm hospitality of its people who make Thailand the "Land of Smiles."

We hope this meeting will not only provide you with unforgettable educational experience, but also an opportunity to network and collaborate with your colleagues. Once again, welcome to Pattaya and we hope you have a pleasant stay.

With kind regards,

Louis Tan
Chair, Asian and Oceanian Section of the International Parkinson and Movement Disorder Society, 2013-2015

Roongroj Bhidayasiri
President, Thai Parkinson's Disease - Movement Disorders Society

Matthew Stern

Dear Colleagues,

On behalf of the International Parkinson and Movement Disorder Society (MDS), I would like to formally welcome you, for the first time, to one of Asia's premier tropical destinations for the 4th Asian and Oceanian Parkinson's Disease and Movement Disorders Congress (AOPMC) in Pattaya, Thailand.

The MDS Asian and Oceanian Section (MDS-AOS) hosts the AOPMC every other year to facilitate communication between clinicians and researchers in the region; disseminate updated knowledge about Movement Disorders; improve quality of life and independence of movement disorders patients and caregivers; and promote research in Movement Disorders within the region.

Pattaya has a relaxing ambience and I encourage you to take some time to enjoy the many leisure activities that this unique destination has to offer; including golf, fishing, scuba diving, botanical gardens, museums and theme parks.

The AOPMC would not be possible without the hard work and dedication of the MDS-AOS and the Thai Parkinson Disease-Movement Disorders Society. Over the past two years, these volunteers have put in countless hours planning what promises to be an extraordinary program.

Again, welcome to Pattaya! I hope you will take part in the many exciting lectures and educational opportunities the 4th Asian and Oceanian Parkinson's Disease and Movement Disorders Congress has to offer.

With kind regards,

Matthew Stern
President, International Parkinson and Movement Disorder Society, 2013-2015




Pattaya City
North Pattaya Road.
Banglamung Chonburi
20150

Dear AOPMC delegates,

Subject: Invitation to AOPMC 2014 in Pattaya, Thailand

On behalf of Pattaya City, it is a great honor for us to serve as a host city of the prestigious 4TH Asian and Oceanian Parkinson's Disease and Movement Disorders Congress (AOPMC) 2014.

Pattaya is known to the world as a vibrant seaside city of Thailand with its beautiful beaches, excellent choice of hotels & resorts, and various recreations for all visitors. In addition to its world reputation as a bustling tourist destination, Pattaya is also positioned as a dynamic congress destination. We emphasize continuous development of the city's infrastructure and facilities as well as quality of service sectors.

The City of Pattaya has played host to many important international meetings such as the Asia Pacific Advertising Festival in March 2014 with more than 800 delegates, the Asia Petrochemical Industry Conference in May 2014 with more 1,000 delegates and a recent International Conference in Sport and Exercise Science in July 2014 which received over 300 delegates.

I hereby would like to extend a most cordial invitation to all delegates of AOPMC 2014 to Pattaya, Thailand. I am confident that you will find the congress fruitful alongside an enjoyable time in Pattaya.

Yours sincerely,

(Mr. Itthiphol Kunplome)
Mayor of Pattaya City

About MDS

The International Parkinson and Movement Disorder Society (MDS) is a professional society of clinicians, scientists, and other healthcare professionals who are interested in Parkinson's disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control. The spectrum of clinical disorders represented by the Society includes, but is not limited to:

Ataxia
Chorea
Dystonia
Gait disorders
Huntington's disease
Myoclonus and startle
Parkinson's disease and parkinsonism
Restless legs syndrome
Stiff person syndrome
Tardive dyskinesia
Tics and Tourette syndrome
Tremor and essential tremor

In recent years, there has been tremendous growth in new diagnostic information, pharmacological and neurosurgical treatments for movement disorders, as well as a greater understanding of impaired motor control function. MDS offers you and your patients an essential link to this knowledge.

In 1985, The *Movement* Disorder Society was founded on the initiative of Professors Stanley Fahn and C. David Marsden, whose leadership and vision guided the expansion of clinical expertise and research in this field. This not-for-profit organization merged in 1992 with the International Medical Society for Motor Disturbances. Publication of the journal *Movement* Disorders began in 1986, and the first International Congress was held in 1990.

In 2013, The *Movement* Disorder Society officially changed its name to the International Parkinson and Movement Disorder Society, in order to recognize the growing importance of Parkinson's disease care and research within the field of Movement Disorders.

Purpose, Mission And Goals

Purpose:

The objective and mission of the Society shall be to advance the neurological sciences pertaining to Movement Disorders; to improve the diagnosis and treatment of patients; to operate exclusively for scientific, scholarly and educational purposes; to encourage research; to provide forums, such as medical journals, scientific symposia and International Congresses, for sharing ideas and for advancing the related clinical and scientific disciplines; to encourage interest and participation in the activities of the Society among healthcare and allied professionals and scientists; and to collaborate with other related professional and lay organizations.

Mission and Goals:

To disseminate knowledge about Movement Disorders by:

- Providing educational programs for clinicians, scientists and the general public designed to advance scientific and clinical knowledge about Movement Disorders
- Sponsoring International Congresses and Symposia on Movement Disorders
- Collaborating with other international organizations and lay groups
- Publishing journals, videotapes and other collateral materials committed to high scientific standards and peer review

To promote research into causes, prevention and treatment of movement disorders by:

- Using the Society's influence and resources to enhance support for research
- Facilitating the dissemination of information about research
- Encouraging the training of basic and clinical scientists in Movement Disorders and related disorders

For the purposes of favorably affecting the care of patients with movement disorders, the Society will provide expertise, advice and guidance to:

- Regulatory agencies to assist them in the approval process of safe and effective therapeutic interventions
- The public (media) and patient support groups by informing them of new research and therapeutic advances
- Governments to assist them in the development of policies that affect support of research and patient care
- Educational efforts to assist in developing standards of training in the specialty




About MDS

MDS Officers (2013-2015)

President
Matthew Stern
USA

President-Elect
Oscar Gershanik
Argentina

Secretary
Francisco Cardoso
Brazil

Secretary-Elect
Claudia Trenkwalder
Germany

Treasurer
Christopher Goetz
USA

Treasurer-Elect
David John Burn
United Kingdom

Past-President
Günther Deuschl
Germany

MDS International Executive Committee

Paolo Barone, *Italy*
Bastiaan Bloem, *Netherlands*
Murat Emre, *Turkey*
Susan Fox, *Canada*
Victor Fung, *Australia*
Etienne Hirsch, *France*
Beom Jeon, *Korea*
Michael Okun, *USA*
Anthony Schapira, *United Kingdom*
Mark Stacy, *USA*

MDS International Secretariat

International Parkinson and
Movement Disorder Society
555 East Wells Street, Suite 1100
Milwaukee, WI 53202-3823 USA
Tel: +1 (414) 276-2145
Fax: +1 (414) 276-3349
E-mail: info@movementdisorders.org
Website: www.movementdisorders.org

About MDS-AOS

MDS Asian and Oceanian Section

The MDS Asian and Oceanian Section (MDS-AOS) serves MDS members from the majority of the Asian continent, as well as Australia, New Zealand and Oceania. The MDS-AOS Executive Committee is chaired by Dr. Louis Tan of the National Neuroscience Institute in Singapore. The MDS-AOS Education Committee is co-chaired by Prof. Madhuri Behari of the All India Institute of Medical Sciences in New Delhi, India and Prof. Shen-Yang Lim of the University of Malaya in Kuala Lumpur, Malaysia. The Asian and Oceanian Section was formed in 2006 at the 10th International Congress of Parkinson's Disease and Movement Disorders in Kyoto, Japan. Since its foundation, MDS-AOS has developed educational programs in India, Sri Lanka, China, Malaysia, the Philippines, Vietnam, Myanmar, Thailand and the United Arab Emirates among other locations. The official MDS-AOS website includes programming and Section information, including details about AOS Regional Partners, leadership, the AOS Training Fellowship Program and a calendar of events.

For further information on MDS-AOS or its educational opportunities, please visit www.movementdisorders.org/MDS/regional-sections/asian-oceanian-section.htm.

MDS-AOS Executive Committee

Chair
Louis Tan
Singapore

Chair-Elect
Nobutaka Hattori
Tokyo

Past Chair
Ruey-Meei Wu
Taipei

Secretary
Roongroj Bhidayasiri
Bangkok

Secretary-Elect
Raymond Rosales
Manila

Treasurer
Yoshikazu Ugawa,
Fukushima

Treasurer-Elect
Carolyn Sue
Sydney

Mandy Au-Yeung
Hong Kong

Jou-Hsien Chen
Taipei

Hee Tae Kim
Seoul

Asha Kishore
Trivandrum

Minh Le
Ho Chi Minh City

Shen-Yang Lim
Kuala Lumpur

Miho Murata
Tokyo

Barry Snow
Auckland

Jonas Yeung
Hong Kong

Baorong Zhang
Hangzhou

AOPMC Organizing Committees

Oversight Committee
Louis Tan, *Singapore* (Chair)
Madhuri Behari, *New Delhi*
Roongroj Bhidayasiri, *Bangkok*
Victor Fung, *Sydney*
Raymond Rosales, *Manila*
Bhim Singhal, *Mumbai*
Yoshikazu Ugawa, *Fukushima*
Ruey-Meei Wu, *Taipei*

Scientific Program Committee
Roongroj Bhidayasiri, *Bangkok* (Chair)
Beom Jeon, *Seoul*
Shen-Yang Lim, *Kuala Lumpur*
Apichart Pisarnpong, *Bangkok*
Raymond Rosales, *Manila*
Suwanna Setthawatcharawanich, *Songkhla*
Hui-Fang Shang, *ChengDu*
Ryosuke Takahashi, *Kyoto*
Eng-King Tan, *Singapore*
Akravudh Viriyavejakul, *Bangkok*

Local Organizing Committee
Roongroj Bhidayasiri (Chair)
Apichart Pisarnpong (Vice-Chair)
Parnsiri Chairangsaris
Solaphat Hemrungrojn
Priya Jagota
Surasa Khongprasert
Witsanu Kumthornthip
Natlada Limotai
Helen Ling
Praween Lolekha
Sarun Nunta-Aree
Sitthi Petchrutchatachart
Sith Sathornsumetee
Vorapun Senanarong
Suwanna Setthawatcharawanich
Oraporn Sitburana
Chutamanee Suthisisang
Surat Tanprawate
Somsak Tiamkao
Akravudh Viriyavejakul

Honorary Advisors
Pairoj Boonkongchuen
Siwaporn Chankrachang
Niphon Poungvarin
Kammant Phanthumchinda
Jithanorm Suwantamee
Somchai Towanabutr



MDS Membership Information

Membership Benefits

Highlights

- Annual Subscription to the print and online **Journal**, *Movement* Disorders
- **New in 2014** – online only journal, *Movement* Disorders-Clinical Practice
- Quarterly **Newsletter** entitled, *Moving Along*
- Access to the Members Only online **Membership Directory**
- **Reduced Registration** rates
- Access to Members Only **CME Activities** and **Web Resources**
- Access to **DVDs**, **Webcasts**, and the MDS **Video Library**
- **Voting Rights** in MDS elections and selection of leadership representatives

Details

- **JOURNALS:** *Movement* Disorders is a peer-reviewed journal covering all topics of the field of basic science. Subscribers receive 14 regular issues of the journal each year. *Movement* Disorders—Clinical Practice is the new exclusively online journal from MDS. Debuting in 2014, the sister publication to *Movement* Disorders, *Movement* Disorders-Clinical Practice seeks to publish peer-reviewed articles that are focused on clinical practice and educational issues relevant to movement disorders neurology.
- **NEWSLETTER:** *Moving Along* - This quarterly newsletter highlights recent and ongoing Society activities, as well as offers a forum for members to exchange ideas and read about noteworthy and upcoming leaders in the field of Movement Disorders.
- **DIRECTORY:** An Online and Mobile Directory which lists addresses, telephone and fax numbers, and e-mail addresses for all current members.
- **REDUCED REGISTRATION:** A reduction in fees charged for participation in the Society's educational programs. Among these are the annual International Congress of Parkinson's Disease and Movement Disorders, and various clinical and scientific programs held separately from the International Congress each year.
- **CME ACTIVITIES, DVDS, TRAINING VIDEOS, and VIDEO LIBRARY:** A unique selection of educational opportunities, including live and online CME/CPD activities and reference material on topics in Movement Disorders.

FREE 12-Month trial Membership! MDS Associate Member Program

Non-Members now have the opportunity to apply for membership with the International Parkinson and Movement Disorder Society (MDS) absolutely free! Delegates of the AOPMC will receive one year of membership, including member benefits*, immediately upon acceptance to the Society, for no charge at all. Eligible delegates** will be contacted approximately one month following the AOPMC; wherein the International Secretariat will provide special instructions to apply online for associate membership with the Society. Interested individuals are encouraged to apply online within 30 days of contact.

**Associate members will not receive the print journal and do not have voting rights.*

***Participants paying the Non-Member registration fee will be eligible to participate in the Associate Member program. This option is not available to those registering as a Junior or Health Professional participant or anyone who registered as part of a group. Only those who have not previously been members of MDS are eligible to apply.*

Join us in 2015! We expect 2015 to be an exciting year for MDS and we look forward to bringing you news of these and other new initiatives through the *Movement* Disorders journals, *Moving Along* newsletter and the MDS website.

For further information, please contact:
International Parkinson and Movement Disorder Society
555 East Wells Street, Suite 1100
Milwaukee, WI 53202 USA
Tel: + 1 (414) 276-2145
Fax: + 1 (414) 276-3349
E-mail: info@movementdisorders.org
Website: www.movementdisorders.org

MDS Education

To better fulfill its global mission of advancing the neurological sciences as they relate to the field of Movement Disorders, MDS is continually expanding its educational portfolio. This growing portfolio offers an increasing variety of high caliber continuing medical education and continuing professional development opportunities in movement disorders. For more information about the opportunities listed in this section, please visit www.movementdisorders.org/MDS/education.htm or e-mail education@movementdisorders.org.

Outreach Education Programs

The following outreach education programs are intended to support movement disorders conferences and meetings in underserved areas. Applications, which include a proposed program, a budget and an online form, are submitted through the MDS website. Corresponding MDS Regional Sections and the MDS Education Committee review outreach education applications throughout the year.

Developing World Education Program

MDS is committed to supporting quality movement disorders education in underserved areas worldwide. Through the Developing World Education Program (DWEP), funds are administered in a flexible support program tailored to the needs of each region. The funds can be used to sponsor faculty travel and accommodation, logistics costs or other course expenses which are approved at the time of application.

Ambassador Program

The Ambassador Program supports the travel of one or two international experts, who are MDS members, to an underserved area for the purposes of education and scientific exchange. Sponsored speakers should deliver a keynote lecture during the meeting.

Visiting Professor Program

The Visiting Professor Program supports the travel of one or two international experts, who are MDS members, to an underserved area for the purposes of education and scientific exchange. During the visit, invited experts should conduct teaching seminars in local hospitals or institutions, participate in grand rounds and/or provide input to further the understanding of movement disorders in the host country.

Online Education

Coffee Break CME

The Coffee Break CME program provides education critical to providing the best care possible. Scientific content is presented in a modular format where each module is focused on a single topic. Each module can be completed in a short period of time and provides the clinician with updated information relevant to their practice. Both standard approaches and new advances are highlighted.

MDS is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. MDS designates this educational activity for a maximum of 2.0 *AMA PRA Category 1 Credits*™ for each module. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Journal CME

Visit the Educational Resources page on the MDS website to view a list of *Movement* Disorders journal articles available for CME credit.

MDS is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. MDS designates this educational activity for a maximum of 1.0 *AMA PRA Category 1 Credits*™ for each module. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Educational DVDs and Streaming Content

As part of its educational mission to expand the availability of educational content, MDS produces enduring materials of select programming. Teaching Courses, Themed Sessions and MDS Video Challenges from the 15th, 16th, 17th, and 18th International Congresses are available to order on the MDS website.

MDS Education

Other Online Education Resources

MDS provides a variety of online educational activities in addition to streaming video and CME programming. The following educational tools are available on the MDS website.

Parkinson and Movement Disorders Curriculum

The Parkinson and Movement Disorders Curriculum provides an overview of movement disorders and a clinical approach to the evaluation and management of common movement disorders. This curriculum is specially developed for trainees, internists, general neurologists and other clinicians interested in acquiring a basic understanding of movement disorders. Interested organizations or institutions may apply to MDS to request permission to use the curriculum.

MDS Video Library

This Members Only library consists of video supplements from the *Movement* Disorders journal since 1986. You may search the Video Library by keyword, author, volume and issue or a combination of these fields.

Live Courses

Through the MDS Regional Sections, MDS offers a robust list of live course learning opportunities. Below is a listing of upcoming courses offered by MDS in the Asian and Oceanian region. Please note that dates and locations are subject to change. For the most up-to-date list of live courses, please visit www.movementdisorders.org/MDS/education.htm.

Deep Brain Stimulation for Movement Disorders
March 13-14, 2015
Seoul, Korea

2nd Middle East Camp for Parkinson's, Movement Disorders and Neuromodulation:
From Neurodegeneration to Neuroregeneration
April 2-4, 2015
Amman, Jordan

The China Continuing Education Classes for Parkinson and Movement Disorders
April 11-12, 2015
Hangzhou, China

Rating Scales and Training Videos

Rating Scales

MDS provides rating scales and related resources published in the *Movement* Disorders journal to physicians, researchers and health professionals interested in Parkinson's disease and other movement disorders. By making these scales available, MDS works to improve the diagnosis of movement disorders and patient care, as well as increase the validity and reliability of research studies. You can access the rating scales below online by visiting www.movementdisorders.org/MDS/Education/Rating-scales.htm. Links to the MDS-UPDRS and UDysRS training programs and rating scales use permission forms are also available through the rating scales link. Licensing fees are free for individual use, but fees may apply for government, nonprofit or industry-funded research.

The following rating scales are currently available:

- Global Assessment Scale for Wilson's Disease (GAS for WD)
- Global Dystonia Scale
- Non-Motor Symptoms Scale (NMSQ) + (Includes NMSQ)
- Quality of Life Essential Tremor Questionnaire (QUEST)
- Rating Scale for Psychogenic Movement Disorders (PMD)
- Rush Dyskinesia Rating Scale*
- Rush Videobased Tic Rating Scale
- UFMG Sydenham's Chorea Rating Scale (USCRS)
- Unified Dyskinesia Rating Scale (UDysRS) +*
- Unified Dystonia Rating Scale (UDRS)
- Unified Multiple System Atrophy Rating Scale (UMSARS)
- Unified Parkinson's Disease Rating Scale (MDS-UPDRS) +*

Asterisk (*) indicates scale was developed by MDS; Plus symbol (+) indicates translations of the scale are available.

MDS Education

Training Videos

MDS publishes several audiovisuals, which are available for sale from the MDS International Secretariat. All materials are available in DVD format. Special reduced rates are available to MDS members. For more information or to place an order, visit www.movementdisorders.org/MDS/Resources/Audio-Visuals-for-Sale.htm.

The titles that are currently available for purchase include:

Instructional Video for Motor Fluctuation Diaries in Parkinson's Disease
Authored by C.G. Goetz, M. Grobman, L. Blasucci, and G.T. Stebbins, this instructional video demonstrates the 3 states of Parkinson's disease, off, on, and on with dyskinesia, with the intent to assist patients in completion of their motor fluctuation diaries. This video is 15 minutes.

Toronto-Western Spasmodic Torticollis Rating Scale TWSTRS Training DVD
Authored by C. Comella, S. Bressman, C.G. Goetz, and A. Lang, this instructional video demonstrates the 10 categories in the TWSTRS scale with verbal and visual examples of scoring in each category. This video is approximately 1 hour and 25 minutes.

Unified Dyskinesia Rating Scale Teaching Program (UDysRS)
Authored by C.G. Goetz, John G. Nutt and G.T. Stebbins. This teaching program provides guidelines and rating examples of the Unified Dyskinesia Rating Scale, a new scale used for evaluating Parkinson's disease. This video is approximately 52 minutes.

Utility of an Objective Dyskinesia Rating Scale for Parkinson's Disease: (Rush Dyskinesia Rating Scale)
Authored by Goetz, et al. *Movement* Disorders Volume 9, Video Supplement. 2. This video provides guidelines and rating examples of the Rush Dyskinesia Rating Scale, a scale widely used for evaluating dyskinesias in Parkinson's disease. This video is approximately 17 minutes.

Unified Parkinson's Disease Rating Scale Training DVD
(1995) Authored by C.G. Goetz, G.T. Stebbins, T. Chmura, S. Fahn, H. Klawans, and C.D. Marsden, this video demonstrates the different categories of the motor section of the UPDRS, with verbal and visual examples of scoring in each category. This video is approximately 1 hour.

Standardized Training Tools for the UPDRS Activities of Daily Living Scale (UPDRS Part II)
(2003) Authored by C.G. Goetz, P.A. Lewitt, and M. Weidenman. *Movement* Disorders Volume 18, Video Supplement. 2. This video provides suggestions on the application and interview techniques for Part II of the UPDRS with patient examples and guidelines for raters. This video is approximately 1 hour and 15 minutes.

The International Parkinson and Movement Disorder Society's Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Training DVD (2010)
The International Parkinson and Movement Disorder Society (MDS)-sponsored new version of the UPDRS is founded on the critique that was formulated by the Task Force for Rating Scales in Parkinson's disease (*Mov Disord* 2003;18:738-750). The MDS-UPDRS has four parts: Part I (non-motor experiences of daily living), Part II (motor experiences of daily living), Part III (motor examination) and Part IV (motor complications). This video is approximately 2 hours and 5 minutes.

Award Information

MDS-AOS Lectureship Awards

The MDS-AOS lectureships were established to honor Professors Yoshikuni Mizuno and Philip Thompson as experts in the field of Movement Disorders and to recognize their contributions as leaders within the International Parkinson and Movement Disorder Society. The lectureships also honor their leadership role in establishing the Asian-Oceanian section (AOS) of the MDS in 2005. The award lectures will be given at the 4th AOPMC during the MDS-AOS Lectureship Plenary session on Sunday, November 30, 2014.

Yoshikuni Mizuno

Dr. Yoshikuni Mizuno is a Professor and the Chairman of the Department of Neurology at Juntendo University School of Medicine. He has been a member of the International Parkinson and Movement Disorder Society since 1992, and has served in many capacities including Treasurer of The *Movement* Disorder Society from 2007-2009, International Executive Committee member from 2001-2004, and MDS-AOS Secretary from 2005-2006.

Dr. Mizuno received medical training at the University of Tokyo and completed his neurological residency at Northwestern University Medical Center in Chicago, Illinois, USA. His research interests have been focused on the study of genetics and treatment of Parkinson's disease. Dr. Mizuno has published more than 250 original articles on Parkinson's disease and related disorders and is particularly interested in the etiology and pathogenesis of Parkinson's disease. He and his collaborators identified the gene (parkin) for an autosomal recessive form of young onset familial Parkinson's disease.

Philip Thompson

Philip Thompson is the Professor of Neurology in the University Department of Medicine at the University of Adelaide and Head of the Department of Neurology at the Royal Adelaide Hospital.

Prof. Thompson trained in Adelaide, Perth and London. His research has focused on the physiology of motor control in normal subjects, the mechanisms of brain stimulation, and disorders of motor control in neurological disease, particularly movement disorders.

Prof. Thompson has served on the International Executive of The Movement Disorder Society for the last 14 years including Secretary of The *Movement* Disorder Society from 2004-2006 and President of The *Movement* Disorder Society from 2009-2011. He was Chairman of the Asian and Oceanian Section of The *Movement* Disorder Society from 2005-2006.

He also has published more than 300 articles and book chapters with special interest in the neurophysiology of motor control, movement disorders and gait.

Yoshikuni Mizuno Award

The Yoshikuni Mizuno Award Lecture was created to recognize an outstanding scholar and inspiring neuroscientist from the AOS region in the field of Movement Disorders. This year's recipient is Professor Nobutaka Hattori.

Prof. Nobutaka Hattori is Professor and Chairman of the Department of Neurology at Juntendo University School of Medicine in Tokyo, Japan. He has been a member of the International Parkinson and Movement Disorder Society since 1998, and has served on multiple committees including the MDS-AOS Executive Committee and the MDS Development Committee.

After receiving his Medical Degree at Juntendo University School of Medicine, he completed his residency in Neurology at Fuji National Hospital in Shizuoka, Japan. He received his PhD in Neurology from Juntendo University where he also studied Molecular Biology. Before beginning his professorship at Juntendo University, he was a Medical Staff in the Department of Neurology at the Tokyo Metropolitan Ebara Hospital. His research interests have been focused on Parkinson's disease, in particularly genetics, pathogensis, and treatment.

Philip Thompson Award

The Philip Thompson Award Lecture is created to recognize an outstanding scholar and role-model clinician from the AOS region in the field of Movement Disorders. This year's recipient is Professor Robert Iansek.

Prof. Robert Iansek is Professor of Geriatric Neurology at Monash University. He is also director of the Victorian Comprehensive Parkinson Program (VCPP) and director of the Clinical Research Centre for Movement Disorders and Gait at Kingston Centre, Monash Health. He is the director of the National Parkinson Foundation Centre of Excellence in Melbourne, the only such centre of excellence in Oceania. Professor Robert Iansek is a neurologist by training and has more than 25 years experience in neurophysiological research in the control of movement, gait disorders and Parkinson's disease. He was instrumental in the development of a unique rehabilitation program for people with Parkinson's disease and established multi-disciplinary teams in care provision for people with Parkinson's disease. He has published nearly 200 articles, books and videos. He was instrumental in the establishment of the Asian and Oceanian section of the International Parkinson and Movement Disorder Society and was a recent Past-Chair. He was recently awarded an Order of Australia Medal (OAM) for his work in Clinical Neurology.




Award Information

Junior Awards

Two Junior Award recipients have been selected based on their significant contribution to the research in the field of Movement Disorders.

Linda Oosterveld, MD

Singapore

Predictors of mortality in Parkinson's disease

Linda Oosterveld, Irene Seah, John Allen, Giselle Reinoso, Kay Yaw Tay, Wing Lok Au, Louis Tan (Singapore)

Objectives: This study aims to identify demographic and clinical features that predict mortality in Parkinson's disease (PD).

Background: Several studies have evaluated predictors of mortality in PD. However, there have been few studies that have examined large study cohorts. [1, 2]

Methods: PD patients seen from 2002 to 2012 were identified from the National Neuroscience Institute Movement Disorder Database. Demographic information and prospectively collected baseline clinical variables assessed within 2 years of diagnosis (where available) were obtained from the Database. All patients were linked to the Singapore Registry of Birth and Death to obtain information on vital status until 2012. Predictor variables included gender, ethnicity, age at diagnosis, UPDRS motor score, Hoehn & Yahr stage (H&Y), clinical subtype, cognitive impairment (MMSE ‹24), years of education and type of PD medication used. Stepwise regression was carried out to evaluate predictors of mortality in PD.

Results: Of the 1786 PD patients identified, 363 (20.3%) had died during the study period. Median survival time from diagnosis was 15.8 years (range 0.3 – 31). All variables obtained were entered into in a stepwise regression model. The factors that did not significantly predict mortality were ethnicity, H&Y, clinical subtype, years of education and type of medication used. Independent predictors of higher mortality were male gender (HR 2.23; 95% CI 1.52 – 3.28), age at diagnosis ›50 years (HR 2.96; 95% CI 1.18 – 7.44), UPDRS motor score =30 (HR 1.72; 95% CI 1.19 – 2.48), and cognitive impairment (HR 2.89; 95% CI 1.91 – 4.37).

Conclusion: In one of the largest studies that evaluated baseline factors to predict mortality in PD, we found that male gender, older age at diagnosis, baseline cognitive impairment and higher baseline UPDRS motor scores were predictors of higher mortality in PD.

References

1. Willis AW, Schootman M, Kung N, et al. Predictors of Survival in Patients with Parkinson Disease. Arch Neurol. 2012;69:601-607

2. Chillag-Talmor O, Giladi N, Linn S, et al. Estimation of Parkinson's disease survival in Israeli men and women, using health maintenance organization pharmacy data in a unique approach. J Neurol 2013;260:62–70

Norihito Uemura, MD

Japan

Neuronopathic Gaucher's disease model of medaka displayed axonal accumulation of alpha-synuclein

Norihito Uemura, Ryosuke Takahashi, Masato Koike, Masato Kinoshita, Tomoko Fujiwara-Ishikawa, Hideaki Matsui, Hodaka Yamakado, Yasuo Uchiyama, Takeshi Todo, Shun-ichi Takeda (Kyoto, Japan)

Objective: To clarify the pathological mechanisms of glucocerebrosidase (GBA) mutations leading to Parkinson's disease (PD).

Background: GBA is a causative gene of Gaucher's disease (GD), a lysosomal storage disease. Heterozygous mutations in this gene have been identified as the most common and strong risk factor for PD. However, the mechanisms behind remain unclear.

Methods: We generated GBA mutant medaka by screening a TILLING (Targeting Induced Local Lesions In Genomes) library and analyzed their phenotype. To clarify the further pathological mechanisms obtained from GBA mutant medaka, we analyzed the primary cortical neurons from mice embryos in the presence or absence of lysosomal inhibitors including bafilomycin, leupeptin and pepstatin.

Results: We generated GBA nonsense mutant (GBA-/-) medaka completely deficient in glucocerebrosidase (GCase) activity. In contrast to the perinatal death of human and mice lacking GCase activity, GBA-/- medaka survived for months, enabling us to analyze the pathological progression. GBA-/- medaka showed abnormal swimming movement at 2 months and died by 5 months. Pathologically, GBA-/- medaka displayed non-selective neuronal loss accompanied by neuroinflammation, lysosomal abnormalities and alpha-synuclein (a-syn) accumulation in spheroids containing autophagosomes. Lysosomal inihibition of primary mouse neurons caused the increased number of both LC3 and a-syn-positive puncta in axons.

Conclusions: GBA-/- medaka is a viable neuronopathic GD model as well as an alpha-synuclein accumulation model. The treatment of primary mouse neurons with lysosomal inhibitors replicated the axonal pathology of GBA-/- medaka, which indicates that GBA deficiency primarily causes lysosomal dysfunction and secondarily causes the spheroids containing autophagosomes where a-syn accumulated. GBA-/- medaka provides novel insights into the pathological mechanisms of GBA mutations leading to PD.

AOPMC Schedule-at-a-Glance

Friday, November 28

- Boehringer-Ingelheim Symposium 12:45 - 13:45
- Allergan Symposium 14:00 - 15:00
- Break
- Novartis Symposium 15:30 - 16:30
- Abbott/UCB Symposium 16:45-17:45
- Opening Ceremony 18:00 - 19:00
- Reception 19:00 - 19:30
- Lundbeck Dinner Symposium 19:30-20:30

Exhibition

Saturday, November 29

- AOPMC Plenary Session 1 8:00 - 9:30
- Break
- AOPMC Plenary Session 2 10:00 - 11:30
- Poster Session Guided Poster Tour 11:30 - 12:30
- Break
- Medtronic Lunch Symposium 13:00 - 14:00
- Break
- Parallel Sessions (3) 14:30 - 16:00
- Break
- Parallel Sessions (3) 16:30 - 18:00
- Break
- Ipsen Dinner Symposium 18:30 - 19:30
- Break
- Video Tournament 20:00 - 22:00

Exhibition

Sunday, November 30

- MDS-AOS Lectures 8:30 - 10:00
- Break
- AOPMC Plenary Session 3 10:30 - 12:00
- Poster Session Guided Poster Tour 12:00 - 13:00
- Break
- Britannia Lunch Symposium 13:30 - 14:30
- Break
- Parallel Sessions (3) 15:00 - 16:30
- Break
- Parallel Sessions (3) 17:00 - 18:30

Exhibition

Exhibition Hours

Location: PEACH Hall A Foyer, Level 3

November 28:	11:00-19:30
November 29:	9:30-18:30
November30:	10:00-18:30

Registration Hours

Location: PEACH Hall A Foyer, Level 3

November 27:	16:00-19:00
November 28:	10:00-18:00
November 29:	7:00-17:00
November30:	7:00-17:00




Scientific Program

Friday, November 28

12:45-13:45 **1101 Opening Symposium**: *Balancing efficacy and adverse events of dopamine agonist in Parkinson's disease management* (Sponsored by Boehringer-Ingelheim)
Location: PEACH Hall A1, Level 3
Chairs: Yoshikuni Mizuno (Japan); Somsak Laptikultham (Thailand)

Challenges in managing the motor symptoms in the early and advanced PD patients
Tim Anderson (New Zealand)

How to deliver the right dose? Practical tips of pramipexole in your clinic
Yoshikuni Mizuno (Japan)

14:00-15:00 **1102 Opening Symposium**: *Complementing clinical examinations in targeting muscles for botulinum toxin injection: Methods of localization by using cervical dystonia as a model* (Sponsored by Allergan)
Location: PEACH Hall A1, Level 3
Chair: Niphon Poungvarin (Thailand)

Injecting botulinum toxin accurately in cervical dystonia-The basics of botulinum toxin therapy and muscle localization
Priya Jagota (Thailand)

Injecting botulinum toxin accurately in cervical dystonia-Complementing with advanced techniques
Erle Lim (Singapore)

15:30-16:30 **1103 Opening Symposium**: *Practical tips for managing complications in advanced Parkinson's disease* (Sponsored by Novartis)
Location: PEACH Hall A2/A3, Level 3
Chairs: Louis Tan (Singapore); Vorapun Senanarong (Thailand)

Tackling the problem of levodopa-induced motor complications
Werner Poewe (Austria)

Research update on clinical management of Parkinson's disease dementia
Nobutaka Hattori (Japan)

16:45-17:45 **1104 Opening Symposium**: *A holistic view of Parkinson's disease* (Sponsored by Abbott-UCB)
Location: PEACH Hall A2/A3, Level 3
Chair: Simon Lewis (Australia)

Nonmotor PD: The real challenges for clinicians
Simon Lewis (Australia)

Going beyond motor symptoms in Parkinson's disease
K. Ray Chaudhuri (United Kingdom)

Optimizing dopaminergic therapy to treat non-motor symptoms in Parkinson's disease
Thomas Kimber (Australia)

18:00-19:00 **Opening Ceremony**
Location: PEACH Hall A1, Level 3

19:00-19:30 **Welcome Reception**
Location: PEACH Hall A Foyer, Level 3

19:30-20:30 **1105 Dinner Symposium**: *Optimizing Parkinson's disease pharmacotherapy* (Sponsored by Lundbeck)
Location: PEACH Hall A2/A3, Level 3
Chair: Somchai Towanabut (Thailand)

Rasagiline as mono- and adjunct therapy to treat Parkinson's disease:
Two randomized, double-blind studies in China
Zhen-Xin Zhang (Peoples Republic of China)

What do we do when the honeymoon is over?
Heinz Reichmann (Germany)

Scientific Program

Saturday, November 29

8:00-9:30 **1201 Plenary Session I:** *Perspectives on Parkinson's disease: Past accomplishments and future possibilities*
Location: PEACH Hall A1, Level 3
Chairs: Oscar Gershanik (Argentina); Kammant Phanthumchinda (Thailand)

8:00 Evolving clinicopathological concepts of Parkinson's disease: Moving beyond the "Decade of the Brain"
Werner Poewe (Austria)

8:30 Indications for using biomarkers for the diagnosis of Parkinson's disease: Options for various scenarios
Anthony Lang (Canada)

9:00 Insights into the natural history of Parkinson's disease: What is the appropriate therapy for patients in different stages?
Victor Fung (Australia)

10:00-11:30 **1202 Plenary Session II:** *Therapeutics in Parkinson's disease: The Asian-Oceanian viewpoint*
Location: PEACH Hall A1, Level 3
Chairs: Yoshikuni Mizuno (Japan); Louis Tan (Singapore)

10:00 Pharmacological, surgical, and infusional therapies in Parkinson's disease: A closer look at the Asian-Oceanian data
Shen-Yang Lim (Malaysia)

10:30 Asian complementary practices in the management of Parkinson's disease: Applications and evidence
Beom Jeon (South Korea)

11:00 The use of neurorestorative technologies in Parkinson's disease: Asian-Oceanian experiences
Ryosuke Takahashi (Japan)

11:30-12:30 **Poster Session**
Location: PEACH Hall A Foyer, Level 3
Poster numbers 1-125
Guided Poster Tours 1-4
(Please see page 25 for details)

13:00-14:00 **1203 Lunch Symposium**: *Partnerships beyond the technology* (Sponsored by Medtronic)
Location: PEACH Hall A2/A3, Level 3
Chair: Apichart Pisarnpong (Thailand)

DBS clinical evidence
Chong Sik Lee (South Korea)

Incorporating DBS in your practice
Elena Moro (France)

14:30-16:00 **1211 Parallel Session:** *Effective management of Parkinson's disease symptoms (motor and non-motor) fluctuations in clinical practice?* (Supported by Roche)
Location: PEACH Hall A1, Level 3
Chairs: Heinz Reichmann (Germany); Chuthaman Suthisisang (Thailand)

14:30 Clinicopathologic correlations of symptom (motor and non-motor) fluctuations in Parkinson's disease
Francisco Cardoso (Brazil)

15:00 Symptom fluctuations in PD: Boundaries beyond recognition
Ruey-Meei Wu (Taiwan)

15:30 How can medications be adjusted to minimize symptom fluctuations? Basic principles
Shengdi Chen (Peoples Republic of China)

14:30-16:00 **1212 Parallel Session:** *Physiological studies in movement disorders: When do clinicians need them and practical interpretation?*
Location: Pattaya 10, Level 4
Chairs: Mitsutoshi Yamamoto (Japan); Kongkiat Kulkantrakorn (Thailand)

14:30 Electrophysiological studies on tremor, myoclonus and dystonia
Ryuji Kaji (Japan)

15:00 Diagnostic and therapeutic roles of rTMS in movement disorders
Yoshikazu Ugawa (Japan)

15:30 Electrophysiological studies in peripheral movement disorders
Jou-Hsien Chen (Taiwan)




Scientific Program

Saturday, November 29

14:30-16:00 **1213 Parallel Session:** *Diagnostic clues from neuroimaging: Practical tips for clinicians*
Location: Pattaya 11, Level 4
Chairs: Saeed Bohlega (Saudi Arabia); Suwanna Setthawatcharawanich (Thailand)

14:30 Parkinsonism
Chong-Sik Lee (South Korea)

15:00 Non-parkinsonian disorders
Mohit Bhatt (India)

15:30 Interactive session: Radiological diagnosis
Oraporn Sitburana (Thailand)

16:30-18:00 **1224 Parallel Session:** *Defrosting Parkinson's disease and understanding "freezing of gait" (FOG) and falls*
Location: PEACH Hall A1, Level 3
Chairs: Robert Iansek (Australia); Jae-Woo Kim (South Korea)

16:30 Subclinical gait and postural dysfunction in early PD: Time for intervention?
Simon Lewis (Australia)

17:00 The physiological and clinical dynamics of FOG and falls
Yasuyuki Okuma (Japan)

17:30 Implementing effective strategies to reduce FOG and falls in PD patients- medications, training, devices and home modifications
Meg Morris (Australia)

16:30-18:00 **1225 Parallel Session:** *Recognition and management of movement disorders conditions in general medical practice*
Location: Pattaya 10, Level 4
Chairs: Yotin Chinvarun (Thailand); Minh Le (Vietnam)

16:30 Movement disorders in intensive care units: Differentiation from mimics and therapeutic priorities
Chusak Limotai (Thailand)

17:00 Movement disorders in autoimmune and neoplastic disorders
Yih-Ru Wu (Taiwan)

17:30 Movement disorders in metabolic disorders
Norlinah Ibrahim (Malaysia)

16:30-18:00 **1226 Parallel Session:** *Chorea in clinical practice*
Location: Pattaya 11, Level 4
Chairs: Bhim Singhal (India); Akravudh Viriyavejakul (Thailand)

16:30 Clinical clues to look for that help define your differential diagnosis
Philip Thompson (Australia)

17:00 Diagnostic work-up in chorea: Practical considerations
Hui Fang Shang (Peoples Republic of China)

17:30 Spectrum and management of drug-induced movement disorders
Sith Sathornsumetee (Thailand)

18:30-19:30 **1227 Dinner Symposium**: *Maximizing the efficacy of botulinum toxin to restore facial symmetry in blepharospasm and hemifacial spasm* (sponsored by Ipsen)
Location: PEACH Hall A2/A3, Level 3
Chair: Witsanu Kumthornthip (Thailand)

Pearls and pitfalls of toxin injections in blepharospasm
Shen-Yang Lim (Malaysia)

Hemifacialspasm and the use of toxin for correction
Raymond Rosales (Philippines)

20:00 - 22:00 **MDS-AOS Video Tournament**
Location: PEACH Hall A1, Level 3
Masters of Tournament: Anthony Lang (Canada) and Victor Fung (Australia)
This is an interactive tournament in which participants will improve diagnostic skills with unique and interesting cases. Teams were formed based on nominations to create multi-country groups. Winning teams will be awarded with medals and certificates.

Scientific Program

Sunday, November 30

8:30 - 10:00 **2201 Plenary Session III**
MDS-AOS Lectureship Awards
Location: PEACH Hall A1, Level 3
Chairs: Roongroj Bhirayasiri (Thailand); Louis Tan (Singapore)

8:30 **Philip Thompson Lectureship Award**
Comprehensive care in Parkinson's disease: Are we ready yet?
Robert Iansek (Australia)

9:00 **Yoshikuni Mizuno Lectureship Award**
Pathogenesis of Parkinson's disease: Mechanistic insights from gene functions of monogenic forms of Parkinson's disease
Nobutaka Hattori (Japan)

9:30 **Junior Award Lectureships**
Linda Oosterveld (Singapore)
Norihito Uemura (Japan)

10:00-10:10 **2202 AOPMC Poster Highlights**
Location: PEACH Hall A1, Level 3
Beom Jeon (Korea)

10:30-12:00 **2203 Plenary Session IV:** *Specific movement disorders in the Asian-Oceanian region: Historical and recent developments*
Location: PEACH Hall A1, Level 3
Chairs: Nobutaka Hattori (Japan); Pairoj Boonkongchuen (Thailand)

10:30 Sex-linked recessive dystonia parkinsonism of Panay
Lilian Lee (Philippines)

11:00 Segawa's disease and Parkinsonism, ALS, Dementia complex of Kii Peninsula
Shigeki Kuzuhara (Japan)

11:30 Common movement disorders in the Asian-Oceanian region
Roongroj Bhidayasiri (Thailand)

12:00-13:00 **Poster Session**
Location: PEACH Hall A Foyer, Level 3
Poster numbers 126-249
Guided Poster Tours 5-8
(Please see page 25 for details)

13:30-14:30 **2204 Lunch Symposium:** *Apomorphine in Parkinson's disease: Clinical evidence and best practice* (Sponsored by Britannia)
Location: PEACH Hall A2/A3, Level 3
Chairs: Beom Jeon (Korea); Siwaporn Chankrachang (Thailand)

Introduction to Apomorphine—Continuous dopaminergic treatment strategies
Teus van Laar (Netherlands)

Experiences in initiating an apomorphine infusion service: Case study
Roongroj Bhidayasiri (Thailand)

15:00-16:30 **2217 Parallel Session:** *Clinical signs that assist clinicians in making a diagnosis of a movement disorder condition*
Location: Pattaya 10, Level 4
Chairs: Baorong Zhang (China); Jithanorm Suwannathemee (Thailand)

15:00 Parkinsonian disorders
Robert Iansek (Australia)

15:30 Hyperkinesias
Asha Kishore (India)

16:00 Psychogenic movement disorders
Mark Hallett (USA)

15:00-16:30 **2218 Parallel Session:** *Surgery of movement disorders*
Location: PEACH Hall A1, Level 3
Chairs: John Thomas (Singapore); Thien Thien Lim (Malaysia)

15:00 Evolution of surgical therapy for PD and dystonia: Where are we now?
Sun Ha Paek (South Korea)

15:30 Various targets of PD surgery: Practical considerations for clinicians
Jawad A. Bajwa (Saudi Arabia)

16:00 Troubleshooting common surgical complications and DBS issues in PD and dystonia
Apichart Pisarnpong (Thailand)




Scientific Program

Sunday, November 30

15:00-16:30 **2219 Parallel Session:** *Management strategies of difficult problems in movement disorders*
Location: Pattaya 11, Level 4
Chairs: Raymond Rosales (Philippines); Supoch Tunlayadechanont (Thailand)

15:00 Management of autonomic dysfunction in parkinsonism
Miho Murata (Japan)

15:30 Management of sleep problems in parkinsonism
Madhuri Behari (India)

16:00 Management of heredodegenerative ataxias
Hidehiro Mizusawa (Japan)

17:00-18:30 **2310 Parallel Session:** *Nutritional considerations and gastrointestinal dysfunction in Parkinson's disease: Practical management*
Location: Pattaya 10, Level 4
Chairs: Mandy Au-Yeung (Hong Kong); Priya Jagota (Thailand)

17:00 Effective management of dysphagia in PD
Sarah Ko (Singapore)

17:30 The contributions of gastrointestinal dysfunction to weight loss in PD: What are the therapeutic options?
K. Ray Chaudhuri (United Kingdom)

18:00 Nutritional tips for PD: Prevent weight loss, optimize absorption of levodopa and enhance musculoskeletal and cognitive fitness
Juei-Jueng Lin (Taiwan)

17:00-18:30 **2311 Parallel Session:** *Movement disorders in vascular diseases and hydrocephalus*
Location: Pattaya 11, Level 4
Chairs: Tim Anderson (New Zealand); Nijasri Suwanwela (Thailand)

17:00 Poststroke movement disorders: Strategic locations, spectrum and management
Jonas Yeung (Hong Kong)

17:30 From 'atherosclerotic' to 'vascular' parkinsonism: Evolving concept and therapeutic principles
Pramod Pal (India)

18:00 Clinical complexity of hydrocephalus and parkinsonism: Optimal balance between medical and surgical management
Masakazu Miyajima (Japan)

17:00-18:30 **2312 Parallel Session:** *Understanding neuropsychiatric manifestations in Parkinson's disease and atypical parkinsonisms*
Location: PEACH Hall A1, Level 3
Chairs: Han-Cheng Wang (Taiwan); Parnsiri Chairangsaris (Thailand)

17:00 Cognitive impairment and behavioral disorders
Hee Tae Kim (South Korea)

17:30 Multisensory hallucinations and delusions
Praween Lolekha (Thailand)

18:00 Impulse control disorders/ Behavioral addictions
Thomas Kimber (Australia)

Faculty and Chair Listing

Anderson, Tim
New Zealand
1101, 2311

Au-Yeung, Mandy
Peoples Republic of China
2310

Bajwa, Jawad
Saudi Arabia
2218

Behari, Madhuri
India
2219

Bhatt, Mohit
India
1213

Bhidayasiri, Roongroj
Thailand
2201, 2203, 2204

Bohlega, Saeed
Saudi Arabia
1213

Boonkongchuen, Pairoj
Thailand
2203

Cardoso, Francisco
Brazil
1211

Chairangsaris, Parnsiri
Thailand
2312

Chankrachang, Siwaporn
Thailand
2204

Chaudhuri, Ray
United Kingdom
1104, 2310

Chen, Jou-Hsien
Taiwan
1212

Chen, Shengdi
Peoples Republic of China
1211

Chinvarun, Yotin
Thailand
1225

Fung, Victor
Australia
1201

Gershanik, Oscar
Argentina
1201

Hallett, Mark
United States
2217

Hattori, Nobutaka
Japan
1103, 2201, 2203

Iansek, Robert
Australia
1224, 2201, 2217

Ibrahim, Norlinah
Malaysia
1225

Jagota, Priya
Thailand
1102, 2310

Jeon, Beom
Korea
1202, 2202, 2204

Kaji, Ryuji
Japan
1212

Kim, Hee Tae
Korea
2312

Kim, Jae-Woo
Korea
1224

Kimber, Thomas
Australia
1104, 2312

Kishore, Asha
India
2217

Ko, Sarah
Singapore
2310

Kulkantrakorn, Kongkiat
Thailand
1212

Kumthornthip, Witsanu
Thailand
1227

Kuzuhara, Shigeki
Japan
2203

Lang, Anthony
Canada
1201

Laptikultham, Somsak
Thailand
1101

Le, Minh
Viet Nam
1225

Lee, Chong Sik
Korea
1203, 1213

Lee, Lillian
Philippines
2203

Lewis, Simon
Australia
1104, 1224

Lim, Erle
Singapore
1102

Lim, Shen-Yang
Malaysia
1202, 1227

Lim, Thien Thien
Malaysia
2218

Limotai, Chusak
Thailand
1225

Lin, Juei-Jueng
Taiwan
2310

Lolekha, Praween
Thailand
2312

Miyajima, Masakazu
Japan
2311

Mizuno, Yoshikuni
Japan
1101, 1202

Mizusawa, Hidehiro
Japan
2219

Moro, Elena
France
1203

Morris, Meg
Australia
1224

Murata, Miho
Japan
2219

Okuma, Yasuyuki
Japan
1224

Paek, Sun-Hae
Korea
2218

Pal, Pramod
India
2311

Phanthumchinda, Kammant
Thailand
1201

Pisarnpong, Apichart
Thailand
1203, 2218

Poewe, Werner
Austria
1103, 1201

Poungvarin, Niphon
Thailand
1102

Reichmann, Heinz
Germany
1105, 1211

Rosales, Raymond
Philippines
1227, 2219

Sathornsumetee, Sith
Thailand
1226




Faculty and Chair Listing

Senanarong, Vorapun
Thailand
1103

Setthawatcharawanich, Suwanna
Thailand
1213

Shang, Hui Fang
Peoples Republic of China
1226

Singhal, Bhim
India
1226

Sitburana, Oraporn
Thailand
1213

Suthisisang, Chuthaman
Thailand
1211

Suwantamee, Jithanorm
Thailand
2217

Suwanwela, Nijasri
Thailand
2311

Takahashi, Ryosuke
Japan
1202

Tan, Louis
Singapore
1103, 1202, 2201

Thomas, John
Singapore
2218

Thompson, Philip
Australia
1226

Towanabut, Somchai
Thailand
1105

Tunlayadechanont, Supch
Thailand
2219

Ugawa, Yoshikazu
Japan
1212

Van Laar, Teus
Netherlands
2204

Viriyavejakul, Akravudh
Thailand
1226

Wang, Han-Cheng
Taiwan
2312

Wu, Ruey-Meei
Taiwan
1211

Wu, Yih-Ru
Taiwan
1225

Yamamoto, Mitsutoshi
Japan
1212

Yeung, Jonas
Hong Kong
2311

Zhang, Baorong
Peoples Republic of China
2217

Zhang, Zhen-Xin
China
1105

Poster Session Schedule

Saturday, November 29, 2014

Poster Session: 11:30 – 12:30
Poster viewing: 8:00 – 18:00
Location: PEACH Hall A Foyer, Level 3

Sunday, November 30, 2014

Poster viewing: 8:00 – 18:00
Poster Session: 12:00 – 13:00
Location: PEACH Hall A Foyer, Level 3

Guided Poster Tours

Guided Poster Tours will take place during the regular poster sessions on November 29-30, 2014. They will be led by members of the AOPMC faculty and the authors will be present to discuss the abstracts. There will be eight total Guided Poster Tours with four simultaneous tours per day on Saturday, November 29 and Sunday November 30. Anyone is welcome to attend. Each tour will highlight approximately ten exceptional posters.

Saturday, November 29, 2014

11:30 – 12:30

Location: PEACH Hall A Foyer, Level 3

Guided Poster Tour 1: Parkinson's disease: Nursing and Allied Health Interventions

Tour Leaders: Maduri Behari (India)
Areerat Suputtitada (Thailand)

Posters featured in this tour:

Poster#	Title
3	Short-term progression of non-motor symptoms in Parkinson 's disease in Singapore
5	Role of Bacopa monnieri as Neuroprotectant in MPTP induced Parkinson's disease (PD) animal model
6	Reach-to-Grasp Actions during ON- and OFF-state of dopaminergic medication in Parkinson's disease: Insights from a barrier task
8	Oral health and nutritional status in patients affected with Parkinson's disease
11	The Use of a Text Messaging Medication Reminder System to Enhance Adherence of Parkinson's disease Patients
12	Quality of Life in Deep Brain Stimulation and Duodenal Levodopa-Carbidopa Infusion Patients
14	Knowledge About Parkinson's Disease in Patients with Parkinson's Disease—A Survey
17	Perception of the Disease in Patients with Parkinson's Disease: Past, Present and Future

Guided Poster Tour 2: Parkinsonism (secondary and parkinsonism-plus)
Parkinsons' disease: Behavioral disorders
Parkinson's disease: Clinical trials

Tour Leaders: Chin Song Lu (Taiwan)
Surat Singmaneesakulchai (Thailand)

Posters featured in this tour:

Poster #	Title
30	Progressive supranuclear palsy showing pure akinesia with gait freezing: Clinicopathological report of an autopsy case
32	The frontal lobe dysfunction and behavior changes in Chinese patients with multiple system atrophy
36	A novel mutation of PDE8B gene in a Japanese family of Autosomal-Dominant Striatal Degeneration
44	Role of astrocytes in functional compensation of the motor deficits after dopaminergic nigrostriatal system degeneration in relation to early Parkinson's disease
52	Prevalence of vitamin D insufficiency and risk of instability and falls in Thai Parkinson's disease patients
54	Comparison of Multi-directional and One-directional patterns of partial body weight support treadmill training in balance improvement in Parkinson's disease
55	Efficacy and safety of Rasagiline in levodopa-treated Korean Parkinson's disease patients with motor fluctuations: Randomized, placebo-controlled, double-blind study
62	Repetitive transcranial magnetic stimulation for freezing of gait in Parkinson's disease
65	Long-term effect of the combination therapy of lidocaine injection and neck corset for drop head in Parkinson's disease
66	Can Speech of Idiopathic Parkinson's Disease in the Early Stage be Pre-Diagnosed by Human Hearing?

Guided Poster Tours

Guided Poster Tour 3: Parkinson's disease: Cognition
Parkinson's disease: Electrophysiology
Parkinson's disease: Neuropharmacology
Parkinson's disease: Phenomenology

Tour Leaders: John Thomas (Singapore)
Natilda Limotai (Thailand)

Posters featured in this tour:

Poster #	Title
73	Prevalence and treatment pattern of Parkinson's disease dementia in Korea
76	Cognitive dysfunction in Parkinson's disease with SWEDDs
77	Relationship between apathy, and cognition /QOL in patients with PD
78	Neuropsychological patterns of impairment in Parkinson's Disease patients in Singapore
82	Prevalence of small fiber neuropathy in idiopathic Parkinson's disease evaluated by Quantitative Sensory Testing: The cross sectional investigational study
83	Efficacy of high-frequency repetitive transcranial magnetic stimulation on depression in Parkinson's disease: A randomized sham-controlled study
84	Voltage Adjustment Effects More on Limb Symptoms than Axial Symptoms in Parkinson's Disease Patients Treated with Subthalamic Nucleus Stimulation
86	Apocyanin, a microglia PHOX inhibitor prevents dopaminergic neuronal degeneration in Lipopolysaccharide induced Parkinson's disease model
97	Investigation of factors associated with psychiatric symptoms in patients with advanced-staged Parkinson's disease
99	Evidence of association between LRKK2 R1628P variant and caffeine intake in Parkinson's disease

Guided Poster Tour 4: Parkinson's disease: Quality of life/caregiver burden
Parkinson's disease: Sleep disorders
Huntington's disease

Tour Leaders: Jee Young Lee (Korea)
Onanong Jitkritsadakul (Thailand)

Posters featured in this tour:

Poster #	Title
103	Changing standing position is the risk factor of falls in Parkinson's disease
106	Gender-related differences in sexual functioning in Parkinson's disease patients
108	Features of non-motor symptoms and determinants of poor Quality of life among different motor subtypes of early Chinese Parkinson's disease
110	Characterizing apathy with other nonmotor symptoms in Parkinson's disease
111	How good do Parkinson's disease (PD) patients turn in bed? A comparative study between PD patients and their spouses using multisite accelerometers
112	The Asian Perspectives of Perceived Burden of Parkinson's Patients with Sleep Disorders: An Assessment of Spousal vs. Offspring Caregivers
115	Improvement of mitochondrial NAD+/FAD+ -linked state-3 respiration by caffeine attenuates quinolinic acid induced motor impairment in rats: Implications in Huntington's disease
117	A 12-month longitudinal study of eye-hand coordination in a visually guided task in Huntington's disease
118	Altered rhythmical eye-hand movement in self-paced and cued tasks in Huntington's disease

Guided Poster Tours

Sunday, November 30, 2014

12:00 – 13:00

Guided Poster Tour 5: Ataxia
Basic science

Tour Leaders: Hui Fang Shang (Peoples Republic of China)
Saknan Bongsebandhu-Phubhakdi (Thailand)

Posters featured in this tour:

Poster #	Title
130	The distribution and progression pattern of adult onset cerebellar ataxias
142	No correlation found between serum biochemical levels of vitamin D and calcium to the status of depression in patients with Parkinson's disease
143	Gray matter volume change correlates with oxidative stress biomarker in Parkinson's disease
148	Neuronopathic Gaucher's disease model of medaka displayed axonal accumulation of alpha-synuclein
149	Respiratory chain analysis of skin fibroblasts in Parkinson's disease patients with mutations of Parkin and glucocerebrosidase 1 genes
154	Optogenetic dopaminergic stimulation in mice
156	The effects of optical stimulation of specific glutamatergic afferent fibers from STn in GPe
158	Structural basis for human glucocerebrosidase 2 deficiencies leading to hereditary ataxias
160	iPS Cell Modeling of Genetic Parkinson's disease

Guided Poster Tour 6: Drug-induced movement disorders
Dystonia
Education in Movement Disorders
Epidemiology

Tour Leaders: Win Min Thit (Myanmar)
Praween Lolekha (Thailand)

Posters featured in this tour:

Poster #	Title
167	Genetic analysis of TOR1A & THAP1 genes in Indian primary dystonia patients
168	Acute dystonic reaction associated with general anesthesia following thymectomy under general anesthesia in patient with myasthenia gravis
178	Awareness of Parkinson's disease in a multiethnic urban Asian setting
180	Increasing Knowledge of Parkinson's disease among Medical Professionals in Southeast Asia: Piloting the Thailand-Myanmar-Laos model (TML model) in continuing medical education
184	Role of microglia-mediated neuroinflammation in the aging process and pathogenesis of Parkinson's disease
187	Prevalence and associated factors of depression in Parkinson's disease patients in Parkinson's disease clinic at Siriraj Hospital
188	Assessing plasma levels of heavy metals in patients of Parkinson's disease
189	Predictors of mortality in Parkinson's disease

Guided Poster Tours

Guided Poster Tour 7: Genetics
Lewy body dementia and other dementias
Neuroimaging

Tour Leaders: Mandy Au Yeung (Hong Kong)
Kulthida Methawasin (Thailand)

Posters featured in this tour:

Poster #	Title
193	A Chinese familial cortical myoclonic tremor with epilepsy pedigree localized on chromosome 8q22.3-q24.13
200	Cytogenetic study and compared with measurements of oxidative stress and PARK2 gene in Parkinson's disease patients
201	Relationship between the Mitochondrial DNA polymerase gamma Gene Polymorphisms with Parkinson disease patients
205	COQ2 gene variant associates with multiple system atrophy
207	CoQ2 gene in patients with dementia
214	Putaminal serotonergic fibers and levodopa-induced dyskinesias in Parkinson's disease patients
219	[18F]FDG PET and [18F]FP-CIT PET studies in Atypical Parkinsonism
222	Whole Brain Voxel Wise Study of Iron Deposits with MRI R2* in Parkinson's disease
223	Diffusion Tensor Imaging of the Brain in Parkinson's Disease: A Whole-Brain Voxel-Wise Approach

Guided Poster Tour 8: Quality of life/caregiver burden in movement disorders
Restless legs syndrome
Tremor
Wilson's disease
This tour will also feature the Late-Breaking Abstracts

Tour Leaders: Tim Anderson (New Zealand)
Surat Tanprawate (Thailand)

Posters featured in this tour:

Poster #	Title
231	Parkinson disease and orthotic treatment
232	Socio-economic impact on oral health-related quality of life of Parkinson's disease patients: Evidence from South India
237	Treatment of Childhood Restless Legs Syndrome
242	Feasibility study report to evaluate the safety and efficacy of unilateral thalamotomy for essential tremor with transcranial MRg focused ultrasound
250	Parathyroid imbalance in Wilson Disease
LBA1	Functional limitation and rehabilitation of Parkinson's disease: Occupational therapy intervention.
LBA2	Wilson's disease: Update on integrated Chinese and western medicine
LBA3	Alpha-synuclein in minor salivary gland as peripheral biomarkers of sporadic Parkinson's disease
LBA4	Suppression of hand tremor at rest in Parkinson's disease but not dystonic tremor by electrical muscle stimulation: A pilot study
LBA5	Access to care from neurologist and subspecialists in Movement Disorders: An analysis of travel distance by patients from the Thailand PD registry database.
LBA7	Determinates of social stigma in Parkinson's disease: A data analysis from the Thailand PD registry database.
LBA8	The effects of subthalamic nucleus Deep Brain Stimulation on cognitive function in patients with Parkinson's disease.
LBA9	Hemichorea and hemiballism in a patient with temporal-parietal lobe infarction after treatment with recombinant tissue plasminogen activator.




Abstract Listing by Topic

Posters 1-125 to be presented on Saturday, November 29, 2014 from 11:30-12:30

Parkinson's disease: Nursing and Allied health interventions

1 Cognitive impairment and depression in patients with Parkinson's disease
Xuedong Qu, LV Wenming (Lanzhou, Peoples Republic of China)

2 Wtihdrawn by author

3 Short-term progression of non-motor symptoms in Parkinson's disease in Singapore
Lai Mun Chew, Prakash Kumar Manharlal, Eng-King Tan, Nivedita Vikas Nadkarni, Weng Kit Lye (Singapore)

4 Nationwide survey of patient knowledge and attitudes towards human experimentation using stem cells or bee venom acupuncture for Parkinson's disease
Yun Kim, Sun Ju Chung, Seong Beom Koh, Young-Su Ju, Jae Woo Kim (Anyang, Gyonggi-do, Korea)

5 Role of Bacopa monnieri as Neuroprotectant in MPTP induced Parkinson's disease animal model
Babita Singh, Rajnish Chaturvedi, Abbas Mahdi, Rajesh Verma, Shivani Pandey (Lucknow, India)

6 Reach-to-Grasp Actions during ON- and OFF-state of dopaminergic medication in Parkinson's disease: Insights from a barrier task
Suweena Khacharoen, Jarugool Tretriluxana, Apichart Pisarnpong, Pakaratee Chaiyawat (Nakhon Pathom, Thailand)

7 Effects of external cues on gait parameters of Parkinson's disease patients: A systematic review
Priscila Rocha, Gustavo Porfirio, Lorenna Aguiar, Henrique Ferraz, Virginia Trevisani (Preston, VIC, Australia)

8 Oral health and nutritional status in patients affected with Parkinson's disease
Asmin Sha (Thrissur, India)

9 Thai Classical Dance: From being part of the culture to being an exercise
Surasa Khongprasert, Roongroj Bhidayasiri, Vijit Kanungsukkasem (Bangkok, Thailand)

10 Knowledge about Parkinson's disease among nurses in Thailand
Nonglak Boonrod, Lalita Kaewwilai, Kamolwan Boonpang, Ratanaruedee Devahastin, Onnalin Jandeaw, Priya Jagota, Onanong Jitkritsadakul, Neil Brenden, Roongroj Bhidayasiri (Bangkok, Thailand)

11 The use of a text messaging medication reminder system to enhance adherence of Parkinson's disease patients.
Lalita Kaewwilai, Nonglak Boonrod, Kamolwan Boonpang, Roongroj Bhidayasiri (Pathumwan, Bangkok, Thailand)

12 Quality of life in Deep Brain Stimulation and Duodenal Levodopa-Carbidopa Infusion patients
Kamolwan Boonpang, Lalita Kaewwilai, Nonglak Boonrod, Ratanaruedee Devahastin, Onnalin Jandeaw, Onanong Jitkritsadakul, Priya Jagota, Roongroj Bhidayasiri (Bangkok, Thailand)

13 Happiness in Parkinson's disease patients and caregivers
Kamolwan Boonpang, Lalita Kaewwilai, Nonglak Boonrod, Priya Jagota, Roongroj Bhidayasiri (Bangkok, Thailand)

14 Knowledge about Parkinson's disease in patients with Parkinson's disease: A survey
Onnalin Jandeaw, Roongroj Bhidayasiri, Priya Jagota, Surat Singmaneesakulchai, Onanong Jitkritsadakul, Nonglak Boonrod, Lalita Kaewwilai, Kamolwan Boonpang, Ratanaruedee Devahastin, Neil Brenden (Bangkok, Thailand)

15 Documentation of reasons for rotigotine patch withdrawal in Parkinson's disease patients
Xiao Deng, Eng-King Tan (Singapore)

16 Contributing factors to indoor and outdoor falls in Parkinson's disease
Mary Danoudis, Meg Morris, Hylton Menz, Jennifer Watts, Anna Murphy, Robert Iansek, Jennifer McGinley (Bentleigh, VIC, Australia)

17 Perception of the disease in patients with Parkinson's disease: past, present and future
Onnalin Jandeaw, Priya Jagota, Surat Singmaneesakulchai, Nonglak Boonrod, Lalita Kaewwilai, Kamolwan Boonpang, Ratanaruedee Devahastin, Neil Brenden, Roongroj Bhidayasiri (Bangkok, Thailand)

18 Drug-related problems in patients with Parkinson's disease identified by pharmacists at the outpatient pharmacy unit
Thanarat Suansanae, Pakawadee Wongpraprutdee, Moncahnok Duangdee, Chuthamanee Suthisisang, Somehai Towanabut (Bangkok, Thailand)

19 Whey protein supplementation increases plasma reduced glutathione, branched-chain amino acids and essential amino acids, but decreases plasma homocysteine in patients with Parkinson's disease
Piyaratana Tosukhowong, Chanchai Boonla, Thasinas Dissayabutra, Lalita Kaewwilai, Chanisa Chotipanich, Juho Joutsa, Roongroj Bhidayasiri (Bangkok, Thailand)

20 Massage therapy: What is the evidence that it is beneficial for Parkinson's patients
Yuka Miyahara, Lalita Kaewwilai, Nonglak Boonrod, Roongroj Bhidayasiri (Bangkok, Thailand)

Abstract Listing by Topic

Parkinsonism (secondary and parkinsonism-plus)

21 Should genetic testing for SCA be included in the diagnostic workup for MSA?
Han-Joon Kim, Beom Jeon, Junghwan Shin, Woong-Woo Lee, Hyeyoung Park, Yu Jin Jung, Jee-Young Lee, Gwanhee Ehm, Chae-Won Shin (Seoul, Korea)

22 An uncommon case of rapid onset vascular parkinsonism following acute deep cerebral venous sinus thrombosis
Thanaboon Worakijthamrongchai, Sirintara Pongpech, Pakorn Jiarakongmun, Ekachat Chanthanapak, Chai Kobkitsuksakul (Bangkok, Thailand)

23 Pontine and extrapontine myelinosis presenting as secondary parkinsonism
Lomesh Bhirud, Manmeet Kaur, Suman Kushwaha, Siddarth Maheshwari (Delhi, India)

24 Autonomic function tests in multiple system atrophy: Cerebellar Type (MSA_C) in Vietnam
Trang Vo, Cong Nguyen (Ho Chi Minh, Viet Nam)

25 Prevalence and clinical characteristics of post-stroke movement disorders after acute ischemic stroke
Yong Bum Kim, Won Tae Yoon (Seoul, Korea)

26 Progressive supranuclear palsy-like phenotype as the presentation of sporadic Creutzfeldt-Jakob disease
Pattamon Panyakaew, Roongroj Bhidayasiri (Bangkok, Thailand)

27 Clinical and MRI features of multiple system atrophy: A report on 26 patients at the Ho Chi Minh City University Medical Center, Vietnam
Tai Tran, Minh Le (Ho Chi Minh City, Viet Nam)

28 Morphological changes in early multiple system atrophy of the cerebellar type
Myung Jun Lee, Joon-Kyung Seoung, Jae-Hyeok Lee, Uicheul Yoon, Eun-Joo Kim (Seoul, Korea)

29 Improvement of neuropsychological test after CSF drainage in normal pressure hydrocephalus: Useful indicator for shunt operation?
Joon Hyun Shin (Cheong Ju Si, Chungcheongbuk-do, Korea)

30 Progressive supranuclear palsy showing pure akinesia with gait freezing: Clinicopathological report of an autopsy case
Eu Jene Choi, Dong Goo Lee, Shin Kwang Khang, Chong Lee (Seoul, Korea)

31 Brain perfusion SPECT and neuropathology of two patients with autopsy-verified Coticobasal Syndrome-Alzheimer's Disease
Sachiko Nakayama, Yumiko Motoi, Shi-Ei Matumoto, Masashi Takanashi, Hideo Mori, Nobutaka Hattori (Tokyo, Japan)

32 The frontal lobe dysfunction and behavior changes in Chinese patients with multiple system atrophy
Bei Cao, Wei Ou, Jing Yang, Qian Wei, HuiFang Shang (Chengdu, Peoples Republic of China)

33 Mild parkinsonian sign in the spectrum of vascular parkinsonian disorders
Tae-Beom Ahn, Dokyung Lee (Seoul, Korea)

34 Creutzfeltd-Jakob Disease: A first case series from a Thai Hospital
Armed Rasheed, Chutanat Yotsarawat, Puchit Sukphulloprat, Praween Lolekha (Pathumthani, Thailand)

35 Two siblings with cerebrotendinous xanthomatosis
Mee Park (Daegu, Korea)

36 A novel mutation of PDE8B gene in a Japanese family of autosomal-dominant striatal degeneration
Kosei Hirata (Tokyo, Japan)

37 Revisiting "Round the Houses" sign in progressive supranuclear palsy
Onanong Jitkritsadakul, Phopsuk Tansuhaj, Roongroj Bhidayasiri (Bangkok, Thailand)

38 Pill rolling tremor caused by critical MCA stenosis
Ummer Karadan, Shafi Shaik, K Salam, V Pradeep Kumar, Mohan Noone (Calicut, India)

Parkinson's disease: Behavioral disorders

39 Prevalence and risk factors of depression among Filipinos with Parkinson's disease
Patricia Ann Canto, Roland Dominic Jamora (Manila, Philippines)

40 The impact of depression on cognitive performances and quality of life in Thai patients with Parkinson's disease
Praween Lolekha, Kongkiat Kulkantrakorn (Bangkok, Thailand)

41 UPPS–P Impulsive Behaviour Scale in Parkinson's disease
Pirada Witoonpanich, Atbin Djamshidian-Tehrani, Andrew Lawrence (Bangkok, Thailand)

42 Behavioral and psychological symptoms in Korean patients with early Parkinson's disease in elderly patients: Preliminary study
Jinyoung Ahn, Hee Tae Kim, Byung Kun Kim (Seoul, Korea)

43 Reduction of motion disability in migrainous rats with Parkinson's disease
Ahmad Ali Lotfinia (Tehran, Iran)

44 Role of astrocytes in functional compensation of the motor deficits after dopaminergic nigrostriatal system degeneration in relation to early Parkinson's disease
Lukasz Olech, Urszula Glowacka, Jadwiga Wardas, Katarzyna Kuter (Kraków, Poland)




Abstract Listing by Topic

45 Improvement of impulse control disorder in Parkinson's disease after Deep Brain Stimulation (of the subthalamic nucleus)
Da-eun Jeong, Hae-Won Shin (Seoul, Korea)

46 The characteristics of non-motor symptoms in drug-naive Parkinson's disease: Analysis between tremor dominant and non-tremor dominant subtypes
Jinyoung Youn, Joon-kyu Moon, Jin Whan Cho, Eungseok Oh, Ji Sun Kim, Wooyoung Jang, Jinse Park (Seoul, Korea)

47 Comparison of the prevalence of anxiety and depression between young-onset Parkinson's disease and typical onset Parkinson's disease patients
Nonglak Boonrod, Lalita Kaewwilai, Kamolwan Boonpang, Priya Jagota, Jirada Sringean, Roongroj Bhidayasiri (Bangkok, Thailand)

48 Depression and voice handicap in Parkinson's disease
Mun Kyung Sunwoo, Jin Yong Hong, Ji Eun Lee, Phil Hyu Lee, Young Sohn (Seongnam, Korea)

49 Cognitive, emotional and social behavioral analysis in 6-OHDA rat model of Parkinson's disease
Neha Mishra, Deepak Sharma (New Delhi, India)

Parkinson's disease: Clinical trials

50 Serum testosterone levels and symptoms of Parkinson's disease
Praween Lolekha, Kongkiat Kulkantrakorn (Bangkok, Thailand)

51 Serum uric acid levels in Thai patients with Parkinson's disease
Piyatnat Wongwan, Praween Lolekha (Banglamung, Chonburi, Thailand)

52 Prevalence of vitamin D insufficiency and risk of instability and falls in Thai Parkinson's disease patients
Praween Lolekha, Kongkiat Kulkantrakorn (Bangkok, Thailand)

53 Alpha-synuclein in minor salivary glands as peripheral biomarkers of sporadic Parkinson's disease
Tao Feng, Yan Gao (Beijing, Peoples Republic of China)

54 Comparison of Multi-directional and One-directional patterns of partial body weight support treadmill training in balance improvement in Parkinson's disease
Raksina Meesathien, Pitagorn Thamronglaohaphan, Teeratorn Pulkes, Pairoj Boonkongchuen (Nonthaburi, Thailand)

55 Efficacy and safety of Rasagiline in levodopa-treated Korean Parkinson's disease patients with motor fluctuations: Randomized, placebo-controlled, double-blind study
Ji Young Yun, Beom Jeon, Jae Woo Kim, Chong Lee, Jong-Min Kim, Jin Whan Cho, Young Sohn, Jee-Young Lee, On Behalf of The PANSORI Study Group (Seoul, Korea)

56 A-synuclein oligomers in human red blood cells as a potential biomarker for Parkinson's disease
Fangfei Li, Tao Feng (Beijing, Peoples Republic of China)

57 Availability of skin biopsy in differential diagnosis between Parkinson's disease and multiple system atrophy
Rie Haga, Yasuo Miki, Chieko Suzuki, Kazuhiro Sugimoto, Kouichi Wakabayashi, Souroku Yagihashi, Masayuki Baba, Masahiko Tomiyama (Aomori, Japan)

58 Determining the driving competency in Parkinson's disease patients
Onanong Jitkritsadakul, Soradech Krootjohn, Chusak Thanawattano, Chanawat Anan, Roongroj Bhidayasiri (Bangkok, Thailand)

59 Lidocaine therapy for lateral truncal deviation in Parkinson's disease
Yoshihiko Furusawa, Takashi Isobe, Kanako Komatsu, Noritaka Wakasugi, Yukio Mizuno, Masahiro Kanai, Yohei Mukai, Takashi Sakamoto, Miho Murata (Kodaira City, Japan)

60 A study of effect of zonisamide in QOL of PD patients
Hidemoto Saiki (Osaka, Japan)

61 The availability of LSVT-BIG for Parkinson's disease patients with wearing-off
Masahiko Tomiyama, Jinichi Nunomura, Megumi Sasaki, Tatsuya Ueno, Rie Haga, Yukihisa Funamizu, Tomoya Kon, Haruo Nishijima, Akira Arai, Chieko Suzuki (Aomori, Japan)

62 Repetitive transcranial magnetic stimulation for freezing of gait in Parkinson's disease
Eungseok Oh, Ji Seon Kim, Sangmin Park, Junggeol Lim, Soo-Kyung Bok, Ae Young Lee (Daejeon, Korea)

63 The prospective study to evaluate the effect of Anti-PD medication on non-motor features of patients with Parkinson's disease at Neurological Clinic, Maharaj Nakorn Chiangmai Hospital: Preliminary results
Juksanee Woranuchkul (Chiangmai, Thailand)

64 Bilateral Recording of Parkinson's Signs with the Parkinson's KinetiGraph: Assessing Its Utility to Evaluate Asymmetric Features
Jirada Sringean, Poonpak Taechalertpaisarn, Onanong Jitkritsadakul, Roongroj Bhidayasiri (Bangkok, Thailand)

Abstract Listing by Topic




Abstract Listing by Topic

Parkinson's disease: Neuropharmacology

85 Hemiballismus due to acute stroke in a Parkinson's disease patient
Shyam Jaiswal, Nilesh Chaudhary, JMK Murthy (Hyderabad, India)

86 Apocyanin, a microglia PHOX inhibitor prevents dopaminergic neuronal degeneration in Lipopolysaccharide induced Parkinson's disease model
Neha Sharma, Neha Sharma, Bimla Nehru (Chandigarh, India)

87 Neuroprotective effects of Withania Someniferais on mice brain: A therapeutic potential drug for Parkinson's disease
Vishnu Dubey, Hamida Aquil (Delhi, India)

88 Iron metabolism in Parkinson's disease
Rajnish Prasad, R Das (Delhi, India)

89 Treatment of camptocormia by the continuous subcutaneous infusions of apomorphine
Petr Kanovsky, Katerina Mensikova, Michaela Kaiserova, Miroslav Vastik (Olomouc, Czech Republic)

Parkinson's disease: Phenomenology

90 Carpal tunnel syndrome in tremor dominant Parkinson's disease
Jong Sam Baik, Jeong Yeon Kim (Seoul, Korea)

91 Three cases of drug-induced dropped head syndrome in Parkinson's disease
Hayato Yabe, Rina Ando, Hirotaka Iwaki, Noriko Nishikawa, Masahiro Nagai, Masahiro Nomoto (Ehime, Japan)

92 Clinical course of migraine in Parkinson's patients
Mahmoud Lotfinia (Tehran, Iran)

93 Quantitative measurement of finger-tapping movements in patients with parkinsonism
Taku Hatano, Ayami Okuzumi, Yasushi Shimo, Shin-ichi Ueno, Akihiko Kandori, Yuko Sano, Nobutaka Hattori (Tokyo, Japan)

94 The effects of motor laterality on working memory in Parkinson's disease
Jee Eun Youn, Ji Sun Kim (Hannam-dong, Youngsan-gu, Korea)

95 Comparison of clinical non-motor symptoms profile between Thai subjects with Parkinson's disease and white Caucasians in London, UK: Exploration of possible ethnic differences
Anna Sauerbier, Lisa Klingelhoefer, K. Ray Chaudhuri, Onanong Jitkritsadakul, Roongroj Bhidayasiri, Panagiotis Zis, Richard Brown, Miriam Parry, Anne Martin, Rona Inniss, Lauren Perkins (London, United Kingdom)

96 Swallowing, voice and freezing of gait in patients with Parkinson's disease
Su Yun Lee, Sang-Myung Cheon, Jae Woo Kim (Busan, Korea)

97 Investigation of factors associated with psychiatric symptoms in patients with advanced-staged Parkinson's disease
Keiichi Nakahara, Ryoichi Kurisaki, Tetsuro Sakamoto, Tetsuji Yamashita, Kazutoshi Uekawa (Uki, Japan)

98 An association study between LRKK2 G2385R variant and caffeine intake in Parkinson's disease
Heidi Pek Hup Chua, Swe Swe Thet Paing, John Allen, Yi Zhao, Prakash Kumar Manharlal, Eng-King Tan (Singapore)

99 Evidence of association between LRKK2 R1628P variant and caffeine intake in Parkinson's disease
Heidi Pek Hup Chua, Swe Swe Thet Paing, John Allen, Yi Zhao, Prakash Kumar Manharlal, Eng-King Tan (Singapore)

100 The use of Sniffin' Stick-16 smell identification test in Thai Parkinson's disease patients: A pilot study
Teeraparp Kijjavijit, Priya Jagota, Nonglak Boonrod, Lalita Kaewwilai, Onanong Jitkritsadakul, Roongroj Bhidayasiri (Bangkok, Thailand)

Parkinson's disease: Quality of life/caregiver burden

101 Validation of Hindi version of NMSS in Indian population
Sweta Singla (Delhi, India)

102 Prevalence, characteristics and risk factors of Idiopathic Parkinson's disease related pain in Parkinson's clinic: A cross-sectional study, Faculty of Medicine, Chiang Mai University
Pisut Chunchongkolkul (Nakornsawan, Thailand)

103 Changing standing position is the risk factor of falls in Parkinson's disease
Pattamon Panyakaew, Chayanin Foongsathaporn, Roongroj Bhidayasiri (Bangkok, Thailand)

104 Clinical pattern of morbidity among Pakistani patients of Parkinson's disease
Tabish Hussain (Islamabad, Pakistan)

105 Quality of sleep, depressive symptoms and quality of life in Parkinson's disease
Kyunghun Kang, Ho-Won Lee, Jong-Geun Seo (Daegu, Korea)

106 Gender-related differences in sexual functioning in Parkinson's disease patients
Onanong Jitkritsadakul, Roongroj Bhidayasiri (Bangkok, Thailand)

Abstract Listing by Topic

107 Non-motor symptoms and health related quality of life in Thai Parkinson's disease patients
Praween Lolekha, Kongkiat Kulkantrakorn (Bangkok, Thailand)

108 Features of non-motor symptoms and determinants of poor quality of life among different motor subtypes of early Chinese Parkinson's disease
Ying Wu (Chengdu, Peoples Republic of China)

109 High frequency repetitive transcranial magnetic stimulation can improve the quality of life in Parkinson's disease
Norbert Kovacs, Samuel Komoly, Endre Pál (Kozarmisleny, Hungary)

Parkinson's disease: Sleep disorders

110 Characterizing apathy with other non-motor symptoms in Parkinson's disease
Junghwan Shin, Jee-Young Lee (Seoul, Korea)

111 How good do Parkinson's disease (PD) patients turn in bed? A comparative study between PD patients and their spouses using multisite accelerometers
Jirada Sringean, Poonpak Taechalertpaisarn, Chusak Thanawattano, Roongroj Bhidayasiri (Bangkok, Thailand)

112 The Asian perspectives of perceived burden of Parkinson's patients with sleep disorders: An assessment of spousal vs. offspring caregivers
Pramon Viwattanakulvanid, Lalita Kaewwilai, Onanong Jitkritsadakul, Neil Brenden, Suwanna Setthawatcharawanich, Nonglak Boonrod, Pawut Mekawichai, Roongroj Bhidayasiri (Bangkok, Thailand)

Huntington's disease

113 Role of hemeoxygenase-1/glycogen synthase kinase-3ß pathway in 3-nitropropionic acid induced neurotoxicity in rats
Puneet Kumar, Aamir Khan (Barnala, Punjab, India)

114 Huntington's disease: Case reports and clinical profile in genetically determined cases from North Eastern Region of India
Amit Barua, Nomal Borah, Parth Deb, Rupjyoti Das, Alpana Hatibaruah (Assam, India)

115 Improvement of mitochondrial NAD+/FAD+ -linked state-3 respiration by caffeine attenuates quinolinic acid induced motor impairment in rats: Implications in Huntington's disease
Jitendriya Mishra, Anil Kumar (Chandigarh, India)

116 Pharmacological modulation of behavioral and biochemical effects resembling Huntington's disease utilizing Sildenafil and Ro-20-1724
Shubham Goyal (Ladwa, Kurukshetra, India)

117 A 12-month longitudinal study of eye-hand coordination in a visually guided task in Huntington's disease
Eng Ann Toh, Michael MacAskill, John Dalrymple-Alford, Daniel Myall, Tim Anderson (Christchurch, New Zealand)

118 Altered rhythmical eye-hand movement in self-paced and cued tasks in Huntington's disease
Eng Ann Toh, Michael MacAskill, John Dalrymple-Alford, Daniel Myall, Tim Anderson (Christchurch, New Zealand)

119 Clinical and genetic characteristics in patients with Huntington's disease from China
Jing Yang, Ke Chen, Qian Wei, Zheng Zhen, Bei Cao, Jean Burgunder, HuiFang Shang (Chengdu, Peoples Republic of China)

Surgical therapy: Parkinson's disease

120 Socioeconomic considerations of pallidotomy and Deep Brain Stimulation for Parkinson's disease in Thailand
Onanong Jitkritsadakul, Krishnapundha Bunyaratavej, Kamolwan Boonpang, Roongroj Bhidayasiri (Bangkok, Thailand)

121 Effectiveness of microelectrode recording in determining STN DBS lead position
Rukmini Kandadai, Rupam Borgohain, Praveen Ankathi, Shaik Jabeen, Meena Kanikannan (Hyderabad, India)

122 Worldwide deep brain stimulation and ablative surgeries for movement disorders utilizing automated and remotely monitored microelectrode recordings
He Huang, Erwin Montgomery, Jason Moyer, Fred Haer, Leland Albright (Greenville, PA, United States)

123 Changes in non-motor symptoms in patients with idiopathic Parkinson's disease after bilateral STN DBS
Rupam Borgohain, Rukmini Kandadai, Praveen Ankathi, Shaik Jabeen, Meena Kanikannan (Hyderabad, AP, India)

124 A five-year follow-up study of STN DBS
Lulu Jiang, Wenbiao Xian, Jing Ye, Jinlong Liu, Chao Yang, Yanmei Liu, Yifan Zheng, Zhong Pei, Ling Chen (Guangzhou, Peoples Republic of China)

125 Deep Brain Stimulation for movement disorders patients in Vietnam: Report of 12 cases
Thi-Hung Nguyen, Khang Le (Ho Chi Minh City, Viet Nam)




Abstract Listing by Topic

Posters 126-250 to be presented on Sunday, November 30, 2014 from 12:00-13:00

Ataxia

126 Finger tapping as a surrogate patient centered outcome for Ataxia: A community-based cross-sectional study in Thai SCA1 patients
Patama Gomutbutra, Megan Brandeland, Surat Tanprawate, Siwaporn Chankrachang (Muang, Thailand)

127 Vestibular performance during high acceleration stimuli correlates with clinical decline in SCA6
Young Eun Huh, Ji Soo Kim, Hyo Jung Kim, Beom Jeon, Jong-Min Kim, Jin Whan Cho, David Zee (Seoul, Korea)

128 Clinical, genetic study and impact factors on decision making for genetic testing of symptomatic and asymptomatic members of large Thai families with spinocerebellar ataxia type 1
Nattakarn Sripratak, Parnsiri Chairangsaris, Pasiri Sittinamsuwan, Chesda Udommongkol (Bangkok, Thailand)

129 Analysis of SCA8, SCA12, SCA17 and SCA19 in Thai patients with unknown spinocerebellar ataxia: A multicenter study
Lulin Choubtum, Teeratorn Pulkes, Pairoj Boonkongchuen, Charungthai Dejthevaporn, Sunsanee Pongpakdee, Suppachok Wetchaphanphesat, Panitha Jindahra, Onanong Jitkritsadakul, Roongroj Bhidayasiri, Suchat Hanchaiphiboolkul (Bangkok, Thailand)

130 The distribution and progression pattern of adult onset cerebellar ataxias
Ji Sun Kim, Jinyoung Youn, Jong Kyu Park, Jin Whan Cho (Seoul, Korea)

131 A second patient with a CACNA1A mutation presenting with paroxysmal tonic upgaze in infancy with subsequent episodic ataxia
Han-Lin Chiang, Deepak Gill, Victor Fung (Taipei, Taiwan)

132 Spinocerebellar ataxia with slow saccade as an unusual presentation of anti-Yo paraneoplastic syndrome
Theerapoj Thammapalert, Panitha Jindahra, Metha Apiwattanakul, Pairoj Boonkongchuen, Teeratorn Pulkes (Bangkok, Thailand)

133 FMR1 premutation alleles in late onset ataxia cohort of India: FXTAS mimics and is common among patients with SCA12 like phenotype
Achal Srivastava, Mohammad Faruq, Varun Suroliya, Deepak Kumar, Ajay Garg, Garima Shukla, Vinay Goyal, Madhuri Behari (New Delhi, India)

134 Withdrawn by author

Basic Science

135 Extracellular prefibrillar forms of alpha-synuclein induced ER stress, autophagic and apoptotic pathways in mouse dopaminergic cells
Amir Tayaranian Marvian, Masoome Khalife, Dina Morshedi, Farhang Aliakbari (Mashhad, Iran)

136 Parkin and multi-PDZ domain-containing protein (Mupp1) associate via a PDZ-mediated interaction and are co-localized in cells
Sang Jin Kim, Won Hee Jang, Sun Hee Choi, Young Joo Jeong, Won Hee Lee, Mooseong Kim, Sha Lom Kim, Dae-Hyun Seog (Busan, Korea)

137 Carrier mediated delivery system bearing dopamine for effective management of parkinsonism
Saurabh Bhargava, Vishal Bhargava (Kanpur, India)

138 Optimizing CNS-delivery by lactyl stearate-coupled liposomes
Nikhil Kapoor, Mani Bhargava, Saurabh Bhargava (Kanpur, India)

139 Withdrawn by author

140 Functional ESCRT machinery is required for the clearance of aggregate-prone proteins associated with neurodegenerative diseases
Ryuji Oshima, Takafumi Hasegawa, Keiichi Tamai, Emiko Miura, Akio Kikuchi, Nobuyuki Tanaka, Atsushi Takeda, Masashi Aoki (Sendai, Japan)

141 Substituted 1, 3, 5-triazine derivatives as adenosine A2A receptor antagonists: Synthesis, structure–activity relationships and molecular modelling studies
Udaya Singh, Hans Bhat (Allahabad, India)

142 No correlation found between serum biochemical levels of vitamin D and calcium to the status of depression in patients with Parkinson's disease
Mohita Shrivastava, Madhuri Behari, Vivekanandhan Subbiah (New Delhi, India)

143 Gray matter volume change correlates with oxidative stress biomarker in Parkinson's disease
Rajini Naduthota, Ketan Jhunjhunwala, Ravi Yadav, Jitender Saini, Rose Dawn Bharath, Rita Christopher, Pramod Pal (Bangalore, India)

144 Effect of age on 2', 3'-cyclic nucleotide phosphodiesterase expression in the substantia nigra pars compacta of Asian-Indians
Jyothi Jairamprasad, Anita Mahadevan, S Shankar, Trichur Raju, Phalguni Alladi (Bangalore, India)

145 Neuroprotective potential of Metformin on neuronal markers in diabetic aging female rats
Vinod Sharma (Delhi, India)

Abstract Listing by Topic

147 Decreased spreading depression susceptibility in Parkinson rat model
Mahmoud Lotfinia (Tehran, Iran)

148 Neuronopathic Gaucher's disease model of medaka displayed axonal accumulation of alpha-synuclein
Norihito Uemura, Ryosuke Takahashi, Masato Koike, Masato Kinoshita, Tomoko Fujiwara-Ishikawa, Hideaki Matsui, Hodaka Yamakado, Yasuo Uchiyama, Takeshi Todo, Shun-ichi Takeda (Kyoto, Japan)

149 Respiratory chain analysis of skin fibroblasts in Parkinson's disease patients with mutations of Parkin and glucocerebrosidase 1 genes
Kawinthra Khwanraj, Somsak Tanrattanakorn, Teeratorn Pulkes, Permphan Dharmasaroja (Nakhon Pathom, Thailand)

150 Alpha-mangostin protects SH-SY5Y neuroblastoma cells from 1-methyl-4-phenylpyridinium-induced apoptosis
Pruchya Janhom, Permphan Dharmasaroja (Bangkok, Thailand)

151 The effect of electrical stimulation of the subthalamic nucleus (STN) or internal part of the globus pallidus (GPi) to primate striatal interneurons
Asuka Nakajima, Yasushi Shimo, Takanori Uka, Nobutaka Hattori (Tokyo, Japan)

152 Cortical spreading depression as a possible therapeutic strategy for movement disorders
Babak Khodaie, Ahmad Ali Lotfinia, Milad Ahmadi, Mahmoud Lotfinia (Tehran, Iran)

153 New and non-invasive therapeutic strategy for Parkinson's disease
Banafshe Khodaie (Tehran, Iran)

154 Optogenetic dopaminergic stimulation in mice
Genko Oyama (Tokyo, Japan)

155 Analysis of the ATP13A2 mutant (PARK9) medaka (Oryzias latipes)
Yosuke Taruno, Hideaki Matsui, Norihito Uemura, Hodaka Yamakado, Ryosuke Takahashi (Kyoto, Japan)

156 The effects of optical stimulation of specific glutamatergic afferent fibers from STn in GPe
Jun Tian, Baorong Zhang (Hangzhou, Peoples Republic of China)

157 Glucocerebosidase activity in skin fibroblast and leucocyte samples in Thai patient with Parkinson's disease
Lukana Ngiwsara, Teeratorn Pulkes, Voraratt Champattanachai, Permphan Dharmasaroja, Somsak Tanrattanakorn, Kawinthra Khwanraj, Lulin Choubtum, Sermsiri Chitphuk, Pairoj Boonkongchuen, James Ketudat-Cairns (Bangkok, Thailand)

158 Structural basis for human glucocerebrosidase 2 deficiencies leading to hereditary ataxias
James Ketudat-Cairns, Ratana Charoenwattanasatien, Risa Mutoh, Salila Pengthaisong, Sompong Sansenya, Lukana Ngiwsara, Jisnuson Svasti, Genji Kurisu (Nakhon Ratchasima, Thailand)

159 Role of Astrocytes in Nigrostriatal System Neurons Degeneration
Katarzyna Kuter, Lukasz Olech, Urszula Glowacka, Jadwiga Wardas (Kraków, Poland)

160 iPS cell modeling of genetic Parkinson's disease
Yasushi Koshiba, Hodaka Yamakado, Asuka Morizane, Tetsuhiro Kikuchi, Kazuko Hasegawa, Haruhisa Inoue, Jun Takahashi, Ryosuke Takahashi (Kyoto, Japan)

161 Novel markers in the early detection of Parkinson's disease: Would serum elemental analysis work?
Suresh Kumar, Shiek Ahmed, Winkins Santosh (Chennai, India)

Choreas (non-Huntington's disease)

162 The last dance: Movement disorder as a presenting feature of acquired immune deficiency syndrome
Eva Lyka Paula Medrano (Manila, Philippines)

163 Progressive chorea as the initial manifestation of systemic lymphoma: A case report and literature review
Ming-Che Kuo, Kang-Chen Hsu, Sung-Chun Tang, Ruey-Meei Wu (Taipei, Taiwan)

Drug-induced movement disorders

164 The impact of Myrtus communis essential oil to increase the formation of the toxic aggregate species of alpha-synuclein and enhancement of the cell death
Farhang Aliakbari, Dina Morshedi (Tehran, Iran)

165 Isolated apraxia of lid opening caused by ropinirole withdrawal
Hee Jin Kim, Seol-Heui Han (Seoul, Korea)

166 Motor dysfunction and mortality by high dose of NMDA receptor blockers
Babak Khodaie (Tehran, Iran)

Dystonia

167 Genetic analysis of TOR1A & THAP1 genes in Indian primary dystonia patients
Subhajit Giri, Tufan Naiya, Shyamal Das, Charulata Sankhla, Kunal Ray, Jharna Ray (Howrah, West Bengal, India)

168 Acute dystonic reaction associated with general anesthesia following thymectomy under general anesthesia in patient with myasthenia gravis
Jiraporn Jitprapaikulsan, Prachaya Srivanitchapoom, Siwarit Rusmeechan, Apichart Pisarnpong (Phitsanulok, Thailand)




Abstract Listing by Topic

169 Sustained relief of tardive-like primary segmental dystonia with prolonged discontinuation of Deep Brain Stimulation
Chae-Won Shin, Beom Jeon (Seoul, Korea)

170 Efficacy of botulinum toxin type A (neu-BoNT/A) in patients with idiopathic cervical dystonia: A single-dose, open-label, dose-response study
Surat Singmaneesakulchai, Lalita Kaewwilai, Roongroj Bhidayasiri (Bangkok, Thailand)

171 Neuropsychiatric comorbidity and quality of life in primary cervical dystonia: A case control study
Neha Rai, Vinay Goyal, Nand Kumar, Garima Shukla, Madhuri Behari (Delhi, India)

172 A case of systemic lupus erythematosus presents as jaw closing dystonia
Hyeo-Il Ma, Suk Yun Kang, Yun Kim (Anyang, Korea)

173 Neuropsychiatric co-morbidity and quality of life in oromandibular dystonia: A case control study
Vinay Goyal, Neha Rai, Nand Kumar, Garima Shukla, Madhuri Behari (New Delhi, India)

174 DBS in dystonic camptocormia: A case report and review
Ravi Yadav, Dwarakanath Srinivas, Pramod Pal, Abu Ansari, Pratibha Surathi (Bangalore, India)

Education in Movement Disorders

175 A course on Parkinson's disease for pharmacists: An evaluation
Priya Jagota, Nonglak Boonrod, Thanarat Suansanae, Roongroj Bhidayasiri (Bangkok, Thailand)

176 Hemimasticatory spasm misdiagnosed as other mimickers: Two case reports
Honghua Yuan, Woong-Woo Lee, Beom Jeon (Changchun, Peoples Republic of China)

177 Pseudo-dysmetria and pseudo-athetoid movement in patients with partial myelitis of the upper cervical cord
Naraporn Prayoonwiwat, Sattawut Wongwiangjunt, Apichart Pisarnpong (Bangkok, Thailand)

178 Awareness of Parkinson's disease in a multiethnic urban Asian setting
Ai Huey Tan, Sik Thien Kong, Jie Ping Schee, Hui Shuang Gan, Kean Hoong Tan, Suet Ker Soo, Cheryl Vanderschaaf, Sara Lew, Ummi Affah Mahamad, Khean Jin Goh, Hoi Sen Yong, Chong-Tin Tan, Shen-Yang Lim, Connie Marras, Kwong Weng Loh, Niki Wai Whye Ho, Quan Hziung Lim, Pei Wen Tan, Chee Chean Lim, Yee Weai Cheong (Kuala Lumpur, Malaysia)

179 The utility of a Thai Parkinson's disease newsletter
Chanawat Anan, Nonglak Boonrod, Roongroj Bhidayasiri, Priya Jagota, Onanong Jitkritsadakul, Lalita Kaewwilai, Kamolwan Boonpang, Pramon Viwattanakulvanid, Neil Brenden, Veeramonl Chantaradee (Bangkok, Thailand)

180 Increasing knowledge of Parkinson's disease among medical professionals in Southeast Asia: Piloting the Thailand-Myanmar-Laos model (TML model) in continuing medical education
Roongroj Bhidayasiri, Onanong Jitkritsadakul, FNU Ohnmar, Neil Brenden, Lalita Kaewwilai, Orapin Singhadej, Ketmanee Phetsirisang, Samlee Plianbangchang, Win Thit (Bangkok, Thailand)

Epidemiology

181 Clinical profiles of motor system of patients with Parkinson's disease at tertiary hospital of North India
Ashok Kumar (Patna, India)

182 Movement disorders in non-Wilsonian cirrhotic patients: The report of prevalence and risk factors from the medical school in agricultural-based community
Kulthida Methawasin, Chatchawan Wongjitrat, Piyanant Chonmaitree, Suthee Rattanamongkolgul, Thanin Asawavichienjinda (Nakornnayok, Thailand)

183 A study on the indication, methods, outcome, quality of reporting of DAT (123I Ioflupane) scan done in an Irish teaching hospital in 2013
Shakya Bhattacharjee, Timothy Lynch (Kolkata, India)

184 Role of microglia-mediated neuroinflammation in the aging process and pathogenesis of Parkinson's disease
In-Uk Song, Kwang-Soo Lee, Jeong Wook Park, Joong-Seok Kim (Yong-In, Korea)

185 Clinical value and effects of silent cerebral ischemic lesions on the prognosis of idiopathic Parkinson's disease
Jeong Wook Park, In-Uk Song, Kwang-Soo Lee (Seoul, Korea)

186 Nutritional status and impairment of daily activities in Thai patients with Parkinson's disease
Jintana Wongkor, Warapone Satheannoppakao, Roongroj Bhidayasiri, Mathuros Tipayamongkholgol (Bangkok, Thailand)

187 Prevalence and associated factors of depression in Parkinson's disease patients in Parkinson's disease clinic at Siriraj Hospital
Pakin Kaewpijit, Nantawat Sitdhiraksa, Supachoke Singhakant, Vorapun Senanarong, Apichart Pisarnpong (Bangkok, Thailand)

Abstract Listing by Topic

188 Assessing plasma levels of heavy metals in patients of Parkinson's disease
Byung Kun Kim, Seok-Jae Kang, Wonjae Sung, Ki-Wook Oh, Hee Tae Kim, Jinyoung Ahn (Seoul, Korea)

189 Predictors of mortality in Parkinson's disease
Linda Oosterveld, Irene Seah, John Allen, Giselle Reinoso, Kay Yaw Tay, Wing Lok Au, Louis Tan (Singapore)

190 Movement disorder in Anti-NMDA encephalopathy: Characteristic and treatment response in Thai patients
Metha Apiwattanakul (Bangkok, Thailand)

191 Vitamin D status in patients with Parkinson's disease
Thi-Hung Nguyen, Trang Le Minh (Ho Chi Minh City, Viet Nam)

Genetics

192 Transcription of LINE-1 retroelements in Rat tissues in response to aging and stress
Somnath Mukherjee (New Delhi, India)

193 A Chinese familial cortical myoclonic tremor with epilepsy pedigree localized on chromosome 8q22.3-q24.13
Zhidong Cen, Fei Xie, Xingjiao Lu, Xiaodong Yang, Wei Luo (Hangzhou, Peoples Republic of China)

194 Parkin mutations in Thai patients with Parkinson's disease: A Thai multicenter study
Chutima Papsing, Aruchalean Taweewongsounton, Pairoj Boonkongchuen, Sunsanee Pongpakdee, Kongkiat Kulkantrakorn, Somsak Tiamkao, Suchat Hanchaiphiboolkul, Teeratorn Pulkes (Bangkok, Thailand)

195 Genetic variants associated with type 2 diabetes mellitus and cognitive impairment in Parkinson's disease
Sun Ju Chung, Juyeon Kim, Young Jin Kim, Kiju Kim, Sooyeoun You, Mi-Jung Kim (Seoul, Korea)

196 To examine the gene expression alterations in a rat's brain by GSM900 MHz
Neeraj Kumar, Vinod Sharma (Barabanki, India)

197 Development of a Drosophila overexpressing a-Synuclein without Omi
Islam Saidul (Shahjadpur, Bangladesh)

198 Exome sequencing and 2nd SNP-GWAS of Japanese Parkinson's disease
Tatsushi Toda, Wataru Satake, Mitsutoshi Yamamoto, Miho Murata, Nobutaka Hattori, Sumio Sugano (Kobe, Japan)

199 Autosomal-dominant parkinsonism with a novel MAPT gene mutation in a specific population of Central Europe (South-Eastern Moravia, Czech Republic)
Katerina Mensikova, Sandra Kurcová, Radek Vodicka, Petr Kanovsky, Marek Godava, Pavel Otruba, Radek Vrtel, Lenka Mikulicová, Michaela Kaiserova, Miroslav Vastik (Olomouc, Czech Republic)

200 Cytogenetic study and compared with measurements of oxidative stress and PARK2 gene in Parkinson's disease patients
Vellingiri Balachandar, Shanmugam Sureshkumar, Balasubramanian Balamuralikrishnan, Subramaniam Mohanadevi, Srinivasalu Shantkriti, Atta Mohd Younis, Shanwaz Dharwadkar, Keshavarao Sasikala (Coimbatore, India)

201 Relationship between the Mitochondrial DNA polymerase gamma Gene Polymorphisms with Parkinson disease patients
Meyyazhagan Arun, Kathannan Sankar, Balasubramanian Balamuralikrishnan, Shanmugam Sureshkumar, Subramaniam Mohanadevi, Shafiahammed Mustaqahammed, Krishnan Padma, Keshavarao Sasikala, Vellingiri Balachandar (Coimbatore, India)

202 Immunological markers, dopamine level and Oxidative Stress markers in Parkinson's disease Patients in South India
Subramaniam Mohanadevi, Balasubramanian Balamuralikrishnan, Shanmugam Sureshkumar, Alagamuthu Karthickkumar, Mahalaxmi Iyer, Ramalingam Jayalakshmi, Keshavarao Sasikala, Vellingiri Balachandar (Coimbatore, India)

203 Mutation scanning of COQ2 gene in ethnic Chinese patients with multiple system atrophy
Chen Yongping, Bi Zhao, Bei Cao, Wei Song, Guo Xiaoyan, Qian Wei, HuiFang Shang (Chengdu, Peoples Republic of China)

204 Cytogenetic study and compared with measurements of selected ions related to oxidative stress and energy metabolism in Alzheimer's Disease Patients South Indian Population
Kathannan Sankar, Subramaniam Mohanadevi, Shanmugam Sureshkumar, Meyyazhagan Arun, Balasubramanian Balamuralikrishnan, Uma Priyadharshini Ponnusamy, Keshavarao Sasikala, Vellingiri Balachandar (Coimbatore, India)

205 COQ2 gene variant associates with multiple system atrophy
Chin-Hsien Lin, Eng-King Tan, Chih-Chao Yang, Han-I Lin, Ruey-Meei Wu (Taipei, Taiwan)




Abstract Listing by Topic

206 Identification of chromosomal alteration and association study of PARK10 gene mutations in Parkinson patients
Divaker Fenn, Divya Fenn, Ramesh Kumar, Meyyazhagan Arun, Shafiahammed Mustaqahammed, Shanmugam Sureshkumar, Shanwaz Dharwadkar, Keshavarao Sasikala, Vellingiri Balachandar (Coimbatore, India)

Lewy body dementia and other dementias in movement disorders

207 CoQ2 gene in patients with dementia
Yinxia Chao, Ebonne Ng, Eng-King Tan (Singapore)

208 Pathologically confirmed DLB presented as clinically dementia of Alzheimer type (DAT)
Yong-Soo Shim (Bucheon-si, Korea)

Myoclonus

209 Case of jerking stiffperson with severe dysautonomia
Nilesh Chaudhary (Hyderabad, India)

210 Clinical profile and outcome in Opsoclonus Myoclonus Syndrome: Experience from tertiary center of North India
Rajesh Verma, Babita Singh (Lucknow, India)

211 Clinical characteristics of negative myoclonus associated with pregabalin
Do-Young Kwon, Moo Hyun Song, Jin Man Jung, Jung Yoon Choi (Ansan-city, Korea)

212 "Bilateral asterixis" atypical presentation in bilateral subdural hematoma
Tipakorn Tumnark (Bangkok, Thailand)

213 Persistent hemifacial spasm: What is it?
Jirada Sringean, Jitlada Samajarn, Jakkrit Amornvit, Iyavut Thaipisuttikul, Nath Pasutharnchat, Roongroj Bhidayasiri (Bangkok, Thailand)

Neuroimaging

214 Putaminal serotonergic fibers and levodopa-induced dyskinesias in Parkinson's disease patients
Jee-Young Lee, Seong Ho Seo, Han-Joon Kim, Jae Sung Lee, Beom Jeon (Seoul, Korea)

215 Apparent diffusion coefficient (ADC) value for Idiopathic Parkinson's disease with unilateral motor symptoms
Byeong Kim, Kyung Wook Kang, Seong-Min Choi, Dong-Eun Kim, Sang Hoon Kim, Seung-Han Lee (Gwangju, Korea)

216 Serum uric acid and nigral iron deposition in Parkinson's disease: A pilot study
Tae-Hyoung Kim, Jae-Hyeok Lee (Yangsan-si, Korea)

217 Age-dependent iron deposition in Pantothenate kinase-associated neurodegeneration
Jae Hyeok Lee, Hyeon-Seok Lee (Yangsan-si, Gyeongsangnam-do, Korea)

218 A machine learning approach for classification of Parkinson's disease and controls using T1-weighted MRI
Bharti Rana, Akanksha Juneja, Mohit Saxena, Sunita Gudwani, S Kumaran, Madhuri Behari, R. Agrawal (New Delhi, India)

219 [18F]FDG PET and [18F]FP-CIT PET studies in Atypical Parkinsonism
Su-Jeong Kim, Chong Lee (Seoul, Korea)

220 Imaging neurodegeneration in movement disorders: A VBM study
Mohit Saxena, Priyanka Bhat, S Kumaran, Vinay Goyal, Madhuri Behari (New Delhi, India)

221 Ataxia with Holmes' and palatal tremor due to midbrain cavernoma
Surachet Eiamthanasinchai, Onanong Jitkritsadakul, Roongroj Bhidayasiri (Bangkok, Thailand)

222 Whole brain voxel wise study of iron deposits with MRI R2* in Parkinson's disease
Jiraporn Laothamatas, Witaya Sungkarat, Ruedeerat Keerativittayayut, Teeratorn Pulkes, Pairoj Boonkongchuen, Supoj Tunlayadechanont, Chonticha Prasartsakulchai, Sunsanee Pongpakdee, T. Supharatpayakorn, J. Praditsilpachote (Bangkok, Thailand)

223 Diffusion tensor imaging of the nrain in Parkinson's disease: A whole-brain voxel-wise approach
Jiraporn Laothamatas, J. Praditsilpachote, Witaya Sungkarat, Teeratorn Pulkes, J. Sirasarn, Pairoj Boonkongchuen, Supoj Tunlayadechanont, Chonticha Prasartsakulchai, Sunsanee Pongpakdee, Ruedeerat Keerativittayayut, T. Supharatpayakorn (Bangkok, Thailand)

224 Functional MRI studies in Parkinson's disease: Complex motor and modified stroop tasks
Witaya Sungkarat, Jiraporn Laothamatas, Teeratorn Pulkes, Pairoj Boonkongchuen, Supoj Tunlayadechanont, Chonticha Prasartsakulchai, Sunsanee Pongpakdee, Ruedeerat Keerativittayayut, T. Supharatpayakorn, J. Praditsilpachote (Bangkok, Thailand)

Neuropharmacology

225 Possible neuroprotective effect of atorvastatin and simvastatin against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms in rats
Anil Kumar (Chandigarh, India)

Abstract Listing by Topic

226 Analysis of the adverse events of pramipexole on Parkinson's disease outpatients: A retrospective chart review
Siripan Phattanarudee, Chutikarn Yanviroonlit, Benjarat Ounpanwat, Saengdao Jaruwisetsri, Siranan Klanbut, Phantipa Sakthong, Roongroj Bhidayasiri (Bangkok, Thailand)

227 Apigenin, primary constituent of water extract of Thunbergia laurifolia Lindl, can block stress related plasma interleukin-6 decrease caused by sodium arsenite
Palarp Sinhaseni (Bangkok, Thailand)

228 Antigenotoxic activity and neuroprotective potential of water extract of aegle marmelos
Amandeep Walia (Amritsar, India)

Quality of life/caregiver burden in movement disorders

229 What should constitute a health related quality of life scale for Parkinson's disease?
Rajeev Aggarwal, Nand Kumar, Vinay Goyal, R M Pandey, Garima Shukla, Sumit Singh, Madhuri Behari (Delhi, India)

230 Symptoms and progression of Alzheimer's disease among South-East Asian population: A Pakistani study
Tabish Hussain, Tumenjavkhlan Sosorburam (Islamabad, Pakistan)

231 Parkinson's disease and orthotic treatment
Banafshe Khodaie (Tehran, Iran)

232 Socio-economic impact on oral health-related quality of life of Parkinson's disease patients: Evidence from South India
Sabin Katpattil (Mangalore, India)

233 The impact of wearing off symptoms in Parkinson's disease patients on patient's quality of life
Lalita Kaewwilai, Nonglak Boonrod, Kamolwan Boonpang, Ratanaruedee Devahastin, Onnalin Jandeaw, Onanong Jitkritsadakul, Roongroj Bhidayasiri (Pathumwan, Bangkok, Thailand)

234 Factors predicting quality of life in hemifacial spasm patients with long-term regular botulinum toxin injections
Suwanna Setthawatcharawanich, Nantaporn Tiyapun, Paveena Nanphan, Montira Vittayakittipong (Hai-Yai, Songkhla, Thailand)

Rating Scales

235 Withdrawn by author

Restless legs syndrome

236 Effect of pregabalin on restless legs syndrome
Pyung-Won Lee (Seongnam-city, Korea)

237 Treatment of childhood restless legs syndrome
Yasunori Oka, Fumie Horiuchi (Hiroshima, Japan)

Surgical therapy: Other movement disorders

238 Delayed focal dystonia after traumatic brain injury treated with contralateral GPi-DBS: Case report
Jie Ren, Guoming Luan (Beijing, Peoples Republic of China)

239 Comparison of unilateral vs. bilateral thalamic Deep Brain Stimulation for essential tremor
Won Hee Lee, Jin Hyuk Seo, Won Seok Chang, Hyun Ho Jung, Jin Woo Chang (Busan, Korea)

Tics/Stereotypies

240 Malignant tics: A rare cause of compressive cervical myelopathy
Gopinath Godhavarma, Manmeet Kaur, Suman Kushwaha, Adlrin Anthony (Delhi, India)

Tremor

241 Structural correlates of cognitive impairments in essential tremor
Ketaki Bhalsing, Keshav J, Jitender Saini, Ravi Yadav, Arun Gupta, Pramod Pal (Bangalore, India)

242 Feasibility study report to evaluate the safety and efficacy of unilateral thalamotomy for essential tremor with transcranial MRg focused ultrasound
Keiichi Abe (Kawasaki Kanagawa, Japan)

243 Perverted head-shaking and positional downbeat nystagmus in essential tremor
Young Eun Kim, Woong-Woo Lee, Ji Soo Kim, Hui-Jun Yang, Ji Young Yun, Han-Joon Kim, Gwanhee Ehm, Jong-Min Kim, Beom Jeon (Anyang-si Gyeonggi-do, Korea)

244 Identifying tremor properties from 3-D gyroscopic assessment to distinguish Parkinson's disease tremor from essential tremor
Sitthi Petchrutchatachart, Chusak Thanawattano, Chanawat Anan, Roongroj Bhidayasiri (Nonthaburi, Thailand)

245 The analysis of tremor frequency of standard clinical examination based on empirical mode decomposition
Chusak Thanawattano, Roongroj Bhidayasiri (Pathumthani, Thailand)

246 Kinematic analysis of hand tremor while walking in Parkinson's disease: Are the features the same as rest tremor?
Roongroj Bhidayasiri, Sitthi Petchrutchatachart, Chanawat Anan, Chusak Thanawattano (Bangkok, Thailand)

Abstract Listing by Topic

247 The relationship between Leucine-rich repeat kinase 2 gene (LRRK2) mutation A419V and Essential tremor (ET)
Ling Ling Chua, Ebonne Ng, Eng-King Tan (Singapore)

248 Evaluation of COQ2 association with essential tremors in Singapore
Ebonne Ng, Eng-King Tan (Singapore)

249 Establishing a novel real-time portable motion capture system to characterize tremor profiles
Kai-Hsiang Chen, Po-Chieh Lin, Yu-Rong Chen, Bing-Shiang Yang, Chin-Hsien Lin (Taichung City, Taiwan)

Wilson's disease, storage and metabolic movement disorders

250 Parathyroid imbalance in Wilson's disease
Sandeep Nair, Remesh Kunjunni, Madhuri Behari, Siddarth Srivastava, Barjesh Sharma, Vivekanandhan Subbiah (Ansari Nagar, India)

Late-Breaking Abstracts

LBA1 Functional limitation and rehabilitation of Parkinson's disease: Occupational therapy intervention.
Sarada Kumar Saha (Mirpur)

LBA2 Wilson's disease: Update on integrated Chinese and western medicine.
Wang XP. (Shanghai, China)

LBA3 Alpha-synuclein in minor salivary glands as peripheral biomarkers of sporadic Parkinson's disease
L.Y. Gao, T. Feng (China)

LBA4 Suppression of hand tremor at rest in Parkinson's disease but not dystonic hand tremor by electrical muscle stimulation: A Pilot study
Onanong Jitkritsadakul, Chusak Thanawattano, Chanawat Anan, Roongroj Bhidayasiri, (Bangkok, Thailand)

LBA5 Access to care from neurologists and subspecialists in Movement Disorders: An analysis of travel distance by patients from the Thailand PD registry database
Roongroj Bhidayasiri, Onanong Jitkritsadakul, Natnipa Wannachai, Lalita Kaewwilai, Kamolwan Boonpang (Bangkok, Thailand)

LBA6 Withdrawn by author

LBA7 Determinates of social stigma in Parkinson's disease: A data analysis from the Thailand PD registry database
Roongroj Bhidayasiri, Natnipa Wannachai, Onanong Jitskritsadakul, Lalita Kaewwilai, Kamolwan Boonpang (Bangkok, Thailand)

LBA8 The effects of subthalamic nucleus Deep Brain Stimulation on cognitive function in patients with Parkinson's disease
Bin Wu-Xiao-Wu Hu-Rong Wu-Chen Chen-Xiao-Ping Wang (Shanghai, China)

LBA9 Hemichorea and hemiballism in a patient with temporal-parietal lobe infarction after treatment with recombinant tissue plasminogen activator
Takenobu Murakami, Tomohiro Wada, Itaru Sasaki, Kenji Yoshida, Mari Segawa, Suguru Kadowaki, Akioh Yoshihara, Shunsuke Kobayashi, Akihiko Hoshi, Yoshikazu Ugawa (Fukushima, Japan)

Exhibit Hall Floor Plan

Location: PEACH Hall A Foyer, Level 3



1. Medtronic
2. Ipsen Pharma
3. UCB
4. Britannia
5. Lundbeck
6. Novartis
7. Lee Wattananan Trading Ltd. and h/p/cosmos
8. GSK
9. inomed Medzintechnik
10. Roche
11. Boehringer Ingelheim
12. Global Kinetics
13. AbbVie
14. St. Jude Medical
15. Allergan

Acknowledgement of Support

The International Parkinson and Movement Disorder Society–Asian and Oceanian Section (MDS-AOS) wishes to acknowledge and thank the following companies for their support:

Platinum

BRITANNIA PHARMACEUTICALS LTD

IPSEN Innovation for patient care

Lundbeck

Medtronic

Gold

NOVARTIS PHARMACEUTICALS

Silver

ALLERGAN®

Boehringer Ingelheim

Roche

ucb Inspired by patients. Driven by science.

Bronze

gsk

4th AOPMC 2014

International Parkinson and Movement Disorder Society Asian & Oceanian Section

THAI PDMDS

Cordially invite you to attend

Complementing clinical examinations in targeting muscles for botulinum toxin injection: Methods of localization by using cervical dystonia as a model

Moderator:
Prof.Niphon Poungvarin, M.D. (Thailand)

Injecting botulinum toxin accurately in cervical dystonia-The basics of botulinum toxin therapy and muscle localization

Dr.Priya Jagota, M.D. (Thailand)

Injecting botulinum toxin accurately in cervical dystonia-Complementing with advanced techniques

Assoc.Prof.Erle Lim, M.D. (Singapore)

Friday,November 28, 2014

14.00 – 15.00

Hall A, PEACH Pattaya Exhibition And Convention Hall
Pattaya, Chonburi, Thailand

ALLERGAN

Managing
Beyond Movement



- Improve symptoms at all stages[1]
- Reduce L-dopa resistant tremor[2]
- Improve ADL and motor functions[1]
- Reduce PD depressive symptoms[3]
- Fast titration in 3 weeks

Boehringer Ingelheim

Sifrol®

Easy & Fast Titration

Week	Suggested dose			Total daily dose (mg)
1	0.125 mg	0.125 mg	0.125 mg	0.375
2	0.25 mg	0.25 mg	0.25 mg	0.75
3	0.5 mg	0.5 mg	0.5 mg	1.5

Further dose incremental by 0.75 mg at weekly intervals up to a maximum of 4.5 mg per day if necessary.

3 Weeks / Doses

Sifrol 0.25 mg

Sifrol 1 mg

References:
1. Lieberman A et al. Neurology 1997; 49: 162-8
2. Meller JC et al. Mov Disord 2005; 20: 903-10
3. Reichmann H et al. CNS Drugs 2003; 17 (13): 963-73

SIFROL® Abbreviated Prescribing Information (CCDS No. 9188-10)

Composition: 1 tablet contains 0.18, 0.7 mg pramipexole base **Indication:** Treatment of signs and symptoms of idiopathic Parkinson's disease and idiopathic Restless Legs Syndrome. **Dosage and administration:** *Parkinson's disease* Dosages should be increased gradually from a starting dose of 0.375 mg per day and then increased every 5 - 7 days. If a further dose increase is necessary the daily dose should be increased by 0.25 mg at weekly intervals up to a maximum dose of 4.5 mg per day. *Restless Legs Syndrome* The recommended starting dose is 0.125 mg taken once daily 2 - 3 hours before bedtime, the dose may be increased every 4 - 7 days to a maximum of 0.75 mg per day. **Special precautions:** Patient with renal impairment a reduced dose is suggested. Hallucinations and confusion are known side effects of treatment with dopamine agonists and levodopa in Parkinson's disease patients. Patients and caregivers should be aware of the fact that abnormal behaviour such as binge eating, compulsive shopping, hypersexuality and pathological gambling have been reported in patients treated with dopaminergic drugs. Patients should be alerted to the potential sedating effects associated with **SIFROL®**, including somnolence and the possibility of falling asleep while engaged in activities of daily living. **Interactions:** Cimetidine may interact with **SIFROL®** resulting in reduced clearance of either or both medication. With amantadine, an interaction is possible. Because of possible additive effects, caution should be advised when patients are taking other sedating medication or alcohol in combination with **SIFROL®**. **Side Effects:** Abnormal behaviour such as binge eating, compulsive shopping, hypersexuality and pathological gambling, abnormal dreams, amnesia, confusion, sensation, delusion, dizziness, dyskinesia, dyspnoea, fatigue, hallucinations, headache, hyperkinesia, hypesthesia, hypotension, insomnia, libido disorders, nausea, paresis, peripheral oedema, pneumonia, pruritus, rash and other hypersensitivity, restlessness, somnolence, sudden onset of sleep, syncope, visual disturbance including vision blurred and visual acuity reduced, vomiting, weight decrease, weight increase.

Boehringer Ingelheim

เบอริงเกอร์ อินเกลไฮม์ (ไทย) จำกัด

ใบอนุญาตโฆษณาเลขที่ ฆท. 1300/2555

06-SP-RMA01 Valid until 10/2014

FOR MEDICAL PROFESSION ONLY

Madopar
Quality of life

Madopar®

levodopa + benserazide



Product Information

MADOPAR 250 / MADOPAR HBS / MADOPAR DISPERSIBLE 125

Contents : Per Madopar 250 tab Levodopa 200 mg, benserazide base 50 mg (as HCl). **Per Madopar HBS cap** Levodopa 100 mg, benserazide base 25 mg (as HCl). **Per Madopar Dispersible 125 tab** Levodopa 100 mg, benserazide base 25 mg (as HCl) **Indications :** Parkinson's disease. Symptoms of Parkinsonism excluding drug-induced Parkinsonism. **Madopar Dispersible 125** Patients w/ dys-phagia or patients w/ early morning & afternoon akinesia, or those who exhibit "delayed on" or "wearing off" phenomenon. **Madopar HBS** Nocturnal immobility. **Dosage :** Initially 62.5 mg tid-qid. Increase mthly until optimal therapeutic effect is achieved. Maintenance: 125 mg 3-6 times daily. Switch from Madopar to Madopar HBS should be made from 1 day to the next, beginning w/ the morning dose. Initially, daily dose & dosing interval should be the same as w/ Madopar, after 2-3 days, gradually increase by about 50% every 2-3 days. **Patients w/ nocturnal immobility** Gradually increase the last evening dose to 250 mg of Madopar HBS. **Administration :** b Best taken at least 1/2 hr before or 1 hr after meals; may be taken w/ meals to reduce GI discomfort. HBS cap: Swallow whole, do not chew/crush. Tab: May be broken into small pieces to facilitate swallowing. Dispersible tab: Disperse in 1/4 glass of water (approx 25-50 mL). Stir before drinking. Consume entire amount w/in 1/2 hr of dissolving the tab. **Contraindications :** Hypersensitivity. Severely decompensated endocrine, renal, hepatic & cardiac disorders. Psychiatric disease w/ a psychotic component or closed-angle glau-coma. Patients <25 yr. Pregnancy. Combination w/ nonselective MAOIs. Avoid MAO-AI & MAO-hepatic & cardiac disorders. Psychiatric disease w/ a psychotic component or closed-angle glau-coma. Patients <25 yr. Pregnancy. Combination w/ nonselective MAOIs. Avoid MAO-AI & MAO-BI combinations. **Special Precautions :** History of MI, coronary insufficiency, cardiac arrhythmia. History of gastric ulcer & osteomalacia. Discontinue 12-48 hr before surgery requiring general anaesth. If patient must undergo surgery w/o Madopar having been w/drawn, avoid anaesth w/ cyclopropane or halothane. Open-angle glaucoma. Monitor liver & kidney function & blood counts during therapy. Diabetes. W/draw gradually. Elderly. Lactation. Co-administration w/ dopaminergic drugs. **Adverse Reactions :** Anorexia, nauses, vomiting, diarrhea, cardiac arrhythmias, ortho-static hypotension, agitation, anxie-ty, insomnia, hallucination, delu-sions, temporal disorientation, depression, ageusia or dysgeusia, dyskinesia, pruritus, rash. Transient elevation of liver transaminases, alkaline phosphatase, rise in BUN, change in urine colour, increased -glutamyltransferase. **Drug Interactions :** Neuroleptics, opioids & anti-hypertensive medications containing reserpine inhibit action of Madopar. Irreversible nonselective MAOIs. Sympathomimetics, antacids, pyri-doxine, protein-rich meal.
P/P: Madopar 250 tab 100's. Madopar HBS cap 100's. Madopar Dispersible 125 tab 100's.

Roche

Roche (Thailand) Ltd.
27-29th Floor, Nara 9 Tower, 519 Phahonyothin Road, Chatuchak
Bangkok 10900 Thailand Tel 0 2918 2300 Fax 0 2937-0083

Further information is available on request
โปรดสำนักงานของเรายินดีให้ข้อมูลเพิ่มเติม

ใบอนุญาตโฆษณายาเลขที่ กท. 695/2553
MAD-1-04-2010-5000

Optimising Parkinson's disease pharmacotherapy

Chaired by Somchai Towanabut, Thailand

Date: Friday 28th November 2014
Time: 19:30–20:30
Venue: Hall A2, A3

19:30–19:35	Chairman's introduction	Somchai Towanabut *Thailand*
19:35–19:55	Rasagiline as monotherapy and adjunct therapy to treat Parkinson's disease: two randomised, double-blind studies in China	Zhen-Xin Zhang *China*
19:55–20:20	What do we do when the honeymoon is over?	Heinz Reichmann *Germany*
20:20–20:30	Panel discussion	Led by Chairman

Satellite symposium at the 4th Asian and Oceanian Parkinson's Disease and Movement Disorders Congress

28th–30th November 2014
Pattaya Exhibition and Convention Hall, Pattaya, Thailand

With educational financial support provided by H. Lundbeck A/S


Medtronic
DBS THERAPY
FOR PARKINSON'S DISEASE
Timing is everything!
Why wait to select the right patients for DBS?
Receive a second opinion from 80 experts with the new patient selection advisor
earlystimulus.medtronic.com
Available on the App Store
ANDROID APP ON Google play
Go online or download Medtronic DBS EARLYSTIMULUS, the new patient selection advisor.
Medtronic DBS
EARLYSTIMULUS
Innovating for life.

A Novartis-sponsored Satellite Symposium
at the 4th Asian and Oceanian Parkinson's
Disease and Movement Disorders Congress

Challenges in recognizing and treating complications in advanced Parkinson's disease

Friday 28th November 2014, 15:30–16:30

Pattaya Exhibition and Convention Hall (PEACH), Royal Cliff Hotel, Pattaya, Thailand

15:30	**Welcome and introduction**
15:35	**Tackling the problem of levodopa-induced motor complications** **Chair:** Assoc. Prof. Louis Tan (Singapore) **Speaker:** Prof. Werner Poewe (Austria)
15:55	**Research update and clinical management of Parkinson's disease dementia** **Chair:** Assoc. Prof. Vorapun Senanarong (Thailand) **Speaker:** Prof. Nobutaka Hattori (Japan)
16:15	**Q&A session**
16:25	**Summary and close**

NOVARTIS
PHARMACEUTICALS

Novartis Pharma AG
CH-4002 Basel, Switzerland

Aug 2014 287248

We welcome you to visit our booth at AOPMC

Inspired by patients. Driven by science.

Abbott
A Promise for Life

Neupro®, for the different dimensions of Parkinson's disease, morning and night*[1]

*Twenty-four hour transdermal delivery of rotigotine to PD patients with early morning motor dysfunction resulted in significant benefits in control of both motor function (p=0.0002) and nocturnal sleep disturbances (p<0.0001).[1]

Used by more than 280,000 patients worldwide**[5]



Neupro

Neupro® is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease as monotherapy or in combination with levadopa, over the course of the disease through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or on-off fluctuations). Please see Global Abbreviated PI before prescribing.

**Patients using Neupro® across both the indications of Parkinson's disease and moderate to severe restless legs syndrome. Data include US, Europe, Australia, Korea, and Mexico, through to July 2014. Source: IMS/MIDAS. 1. Trenkwalder C, Kies B, Rudzinska M, et al; and RECOVER Study Group. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011; 26(1): 90-99. 2. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007; 68(4): 272-276. 3. LeWitt PA, Lyons KE, Pahwa R; for SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER study. Neurology. 2007; 68(16): 1262-1267. 4. Neupro® [summary of product characteristics]. European Medicines Agency Website. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000926/WC500026397.pdf. Updated August 2012. Accessed October 19, 2012. 5. IMS/MIDAS data. 6. Trenkwalder C, Kies B, Daszegyi P, et al. Rotigotine transdermal system for the management of motor function and sleep disturbances in Parkinson's disease: results from a 1-year, open-label extension of the RECOVER study. Basal Ganglia. 2012; 2(2): 79-85. 7. Elmer LW, Surmann E, Boroojerdi B, Jankovic J. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension. Parkinsonism Relat Disord. 2012; 18(5): 488-493. 8. Ceballos-Baumann A, Hack H-J. Rotigotine transdermal patch in combination therapy for Parkinson's disease - observations in routine clinical practice. Curr Med Res Opin. 2011; 27(10): 1899-1905. 9. Chaudhuri KR, Martinez-Martin P, Antonini A, et al. Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord. 2013; 19(7): 660-665.

SEA-0019-102014 T995-2014-021

International Parkinson and
Movement Disorder Society

Certifies that

has attended the 4th Asian and Oceanian Parkinson's Disease and Movement Disorders Congress in Pattaya, Thailand on November 28-30, 2014.

Matthew Stern
President,
International Parkinson and
Movement Disorder Society,
2013 - 2015

Louis Tan
Chair,
4th AOPMC Oversight Committee
2013 – 2015

Roongroj Bhidayasiri
Chair,
4th AOPMC Scientific Program Committee
2013-2015

2014–2015
MDS Educational Calendar

International Parkinson and Movement Disorder Society

Deep Brain Stimulation for Movement Disorders – Milan
December 5-6, 2014
Milan, Italy

Sleep in Movement Disorders
January 30-31, 2015
Barcelona, Spain

MDS-PAS School for Young Neurologists
February 21-22, 2015
Atlanta, GA, USA

Deep Brain Stimulation for Movement Disorders – Barcelona
March 5-6, 2015
Barcelona, Spain

Deep Brain Stimulation for Movement Disorders
March 13-14, 2015
Seoul, Korea

2nd Middle East Camp for Parkinson's, Movement Disorders and Neuromodulation
April 2-4, 2015

Fostering New Directions in Parkinson's Research
May 4-9, 2015
White Plains, NY, USA

Diagnosis and Treatment of Cognitive Dysfunction in Movement Disorders
Coming in 2015
Newcastle Upon Tyne, UK

MDS Dystonia Educational Course for Industry Professionals
January 13, 2015
Lisbon, Portugal

Alpha-Synuclein: The Gateway to Parkinsonism – Innsbruck
February 11-13, 2015
Innsbruck, Austria

MDS-ES Winter School for Young Neurologists
February 25-27, 2015
Tel-Aviv, Israel

Evidence Based Medicine Update on Treatments for Parkinson's Disease
March 13, 2015
Salvador da Bahia, Brazil

Bridges and Boundaries in Movement Disorders: The Role of Neuroimaging
March 20-21, 2015
Pisa, Italy

The China Continuing Education Classes for Parkinson and Movement Disorders
April 11-12, 2015
Hangzhou, China

Deep Brain Stimulation for Movement Disorders – Grenoble
September 10-11, 2015
Grenoble, France

For our full list of courses, visit www.movementdisorders.org/MDS/education.htm

• CHICAGO • PARIS • BUENOS AIRES • TORONTO • DUBLIN • SYDNEY • STOCKHOLM • SAN DIEGO •

WASHINGTON DC • MUNICH • ORLANDO • VIENNA • NEW YORK • BARCELONA • MIAMI • ROME • NEW ORLEANS • KYOTO • ISTANBUL

International Parkinson and Movement Disorder Society

SAVE THE DATE

WWW.MDSCONGRESS2015.ORG

IMPORTANT DATES

DECEMBER 3, 2014
Registration Opens

JANUARY 8, 2015
Abstract Submission Closes

APRIL 17, 2015
Early Registration Deadline

MAY 15, 2015
Final Pre-Registration Deadline

JUNE 14-18, 2015
19th International Congress of Parkinson's Disease and Movement Disorders



19TH INTERNATIONAL CONGRESS OF PARKINSON'S DISEASE AND MOVEMENT DISORDERS

JUNE 14-18
2015
SAN DIEGO, CA, USA

WASHINGTON DC • MUNICH • ORLANDO • VIENNA • NEW YORK • BARCELONA • MIAMI • ROME • NEW ORLEANS • KYOTO • ISTANBUL

• CHICAGO • PARIS • BUENOS AIRES • TORONTO • DUBLIN • SYDNEY • STOCKHOLM • SAN DIEGO •